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Staging is critical in the management of cancer. Sentinel lymph node (SLN) biopsy is one 
method used in the assessment of cancer spread. SLN procedures are standard practice in 
the management of some cancers although; these procedures have only recently been 
developed and refined. SLN procedures are commonly used in the management of 
melanomas and breast cancers in patients with no evidence of metastatic disease on 
clinical exam. 
 
SLN procedures include detection, localization, and assessment of SLNs. The 
detection/localization components vary in technique and rates of success. The procedures 
with the least number of detection/localization techniques generally include the use of 
blue dye or the use of a radiotracer with intraoperative gamma counting. The most 
complex procedures involve the use of blue dye, the use of a radiotracer with 
preoperative gamma imaging and preoperative gamma counting, intraoperative gamma 
counting, or some combination of these techniques. 
 
The ideal procedure for SLN would include all the listed techniques however; all 
facilities do not incorporate the most complete procedure, for different reasons. An 
investigation using a small FOV (5 in x 5 in) gamma camera  intraoperatively for SLN 
procedures in melanoma and breast cancer patients was performed. A smaller FOV 
camera is capable of obtaining some of the same information as a conventional gamma 
camera. It is possible that centers, which do not or are not able to take advantage of 
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preoperative imaging, may find the use of a smaller FOV gamma camera in the operating 
room useful.  
 
The investigation consisted of a total of 41 patients; it was split into two studies, Study 1: 
melanoma and study 2: breast cancer. The melanoma study found the added use of a 
smaller FOV camera under the parameters of this study to be minimal. Study 2 was 
broken into two branches; branch 1: camera/probe/dye and branch 2: probe/dye, for a 
comparison study. Comparing the two branches did not show the smaller FOV camera to 








Staging of disease is an important factor in determining a cancer patient’s management 
and prognosis. One component of staging melanoma and breast cancer is assessment of 
the lymph nodes local and regional to disease. Historically, assessment has involved 
resection and histological evaluation of a significant number of nodes; excision and 
evaluation of 10 to 30 nodes is not uncommon. Elective regional lymph node dissection 
(ELND), extensive removal of local and regional nodes near a melanoma, and full 
axillary lymph node dissection (FALD), removal of most axillary nodes near breast 
cancer, have been components of standard-of-care management of melanoma and breast 
cancer patients, respectively. Such resections and analyses are useful for some patients, 
but for many patients, particularly those with no pre-surgical clinical indications of 
metastases, such procedures often result in added morbidity without added survival 
benefit. 
 
Sentinel lymph node (SLN) biopsy is an alternative to a radical lymph node resection for 
lymphatic assessments. In a SLN biopsy procedure, only one or a few key nodes, referred 
to as SLNs, are excised. The premise behind SLN procedures is metastasis of cancer is 
systematic. That is, cancer spread is first local, then regional, then distant. With this 
assumption a negative examination of locally assessed nodes would make an 
investigation of regional or distant spread unnecessary. By locating and assessing SLNs, 
the nodes nearest a cancer, a SLN procedure limits or eliminates additional 
investigations, if the SLNs contain no evidence of metastasis then. Toward the goal of 
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high confidence as regards the absence of metastasis in SLNs, SLN procedures include a 
more extensive histological evaluation of nodes considered SLNs. The limited number 
nodes excised in SLN procedures are generally evaluated much more extensively than the 
numerous nodes excised in ELNDs and FALDs. 
 
Currently, there are several forms of SLN procedures; most forms are similar in that they 
involve the same fundamental techniques. However, the rates of success of the various 
procedures vary greatly; in fact, the success rates of some vary greatly when simply 
conducted by different practitioners. The least complex of existing SLN procedures, as 
regards number of techniques involved, includes those that use intraoperative 
visualization of blue dye or those that use intraoperative detection of a radiotracer with a 
gamma counting probe. In blue-dye only procedures, the dye diffuses from near a cancer 
into the lymphatic system and into nodes; In radiotracer only procedures, the radiotracer 
diffuses from near a cancer into the lymphatic system and into the nodes. 
 
More complex procedures are those that use both techniques and those that include 
preoperative imaging with a gamma camera. A procedure is considered successful if 
SLNs are identified, removed, and assessed. Preoperative imaging is an important 
component of the SLN procedure in which radioactivity is used; however, it is not 
performed or not performed well at some institutions. Adding intraoperative imaging to 
the SLN procedure could be beneficial to many institutions. It is possible for 
intraoperative imaging to provide much of the information that some preoperative 
imaging provides and it could be more practical at some institutions 
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The most inclusive method with preoperative imaging would be recommended for any 
center performing SLN biopsies; there is no substitute for preoperative imaging 
performed by a skilled nuclear medicine technologist. Intraoperative imaging with a 
relatively small FOV gamma camera should not be used to replace preoperative imaging 
or the intraoperative use of a gamma probe but, should be used concurrently with these 
procedures. The benefits of using a small field-of-view camera during SLN procedures 
for breast cancer and melanoma are unknown at this time. 
 
A clinical evaluation was performed to investigate the added benefit of adding a small 
FOV gamma camera to SLN biopsies and investigating the operating procedures after 
adding the small FOV camera to surgery. The investigation was split into two different 
studies: Study 1 melanoma and study 2 breast cancer. Study 2 was defined into a more 
explicit study containing branch 1and branch 2. Each investigation consisted of a skilled 
surgeon, skilled nuclear medicine technologist, experienced scientist and a gamma 
camera with a 5 in x 5 in FOV GammaCam (Gamma Medica, Northridge, CA). 
 
The outcome of the studies was specific to the details of each study. The details of each 
study make it possible for future investigations of a relatively small FOV camera used 
intraoperatively for SLN procedures. Changing the variables such as the type of cancer, 
the skill level of the surgeon and other details may result in very different outcome for the 
value of such a camera. The details of each study and much more are explained 
throughout this paper. 
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The layout of this paper is as follows: 
Chapter 2 gives background information about the diseases melanoma and breast cancer. 
This chapter lays out general information which may help understand the idea behind 
sentinel lymph node dissection however, this chapter is not critical to understanding 
SLNs or gamma cameras. 
Chapter 3 provides detailed information on SLN biopsies. This chapter explains the 
concept and how it the procedure is performed as well as giving the history of SLN 
procedures. 
Chapter 4 explains gamma detection devices, the history of the devices and how they are 
used in regards to SLN biopsies. 
Chapter 5 gives explicit details about the methods used for this investigation as well as 
listing the specific devices used. The chapter divides the methods by each of the two 
studies in this investigation. 
Chapter 6 presents the results observed in this investigation. The results are presented 
separately for each study in the investigation. 
Chapter 7 is the discussion about the results observed in the investigation. This chapter 
gives possible explanations for the results of this investigation. The discussion chapter is 
divided into the two studies.  
Chapter 8 is the final chapter of this document; it has the conclusions, observations and 
future directions. The conclusion gives a summary of the entire investigation and its 
significance. The observation section of this chapter reveals some anecdotal information 
on small FOV gamma cameras. The chapter ends with possible future investigations to 
further the research involving intraoperative gamma cameras and SLN procedures.  
-5-  





2.1.1. Melanoma Types 
In 1787, John Hunter reported the first documented case of cutaneous melanoma [Balch 
85]. He did not call his findings melanoma, but he was the first to describe a form of the 
disease we now call melanoma. In 1907, William Handley described the first reasonable 
surgical approach for the management of metastatic melanoma. In his report, which was 
based on a single autopsy, he suggested removal of obvious disease, removal of two 
inches of subcutaneaous tissue, and the performance of a radical local regional lymph 
node resection. His guidelines for the management of melanoma were followed for 50 
years [Balch 85, Eady 03]. Most of the guidelines are still part of standard care. What is 
no longer considered standard of care in all cases is performance of a radical local 
regional lymph node resection. 
 
Fifty percent or more of all cancers are skin cancers. Melanoma accounts for only about 
four percent of all skin cancers; however, it is the cause of seventy-nine percent of all 
deaths due to skin cancer [Statius 99]. Melanoma is a more serious skin cancer than most, 
because it can readily spread through the lymph channels and blood to infect other parts 
of the body [Statius 99]. Melanoma develops in melanocytes, pigment cells that lie 
beneath the outermost layer of epidermis but above the dermis layer. Melanoma can 
occur most anywhere on the skin; it can also occur in the eye and in relatively rare 
instances in the membranes of the nasal passages, oral, pharayngeal mucosa, and vaginal 
and anal mucosa. 
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Detection of melanoma starts with here are common signs and symptoms to look for in 
detecting melanoma. The primary features to look for when detecting/looking for 
melanoma is change, a change in the skin lesion, mole, or freckle [Balch 85]. A mole on 
the skin is usually round and seems to be evenly colored. Moles may appear during a 
person’s lifetime or they are present from birth. Usually the first sign of a problem is 
when a mole or lesion begins to change. A heuristic method of detecting change is the 
ABCD rule. The rule notes general characteristics to consistently observe. First look for 
asymmetry in the lesions: when half of lesion seems to be apparently different, there is 
crust raising, or the surface begins to crust. Secondly pay attention to the borders of the 
lesion. Look for indentations or notches around the border. Next observe color, normally 
a lesion will start to become dark or appear patchy. The D represents the diameter of the 
lesion. If the lesion begins to grow the diameter will increase [Zalaudak 03].There are 
many other symptoms to be aware of such as itching, bleeding, ulcerations, swollen 
lymph nodes and more. However observing the most common symptoms can often help 
lead to early detection. 
 
Cutaneous melanoma is the most common type of melanoma. An estimated 55,000 
Americans will be diagnosed with cutaneous melanoma; fourteen percent of whom will 
die of the disease [Tsao 04]. There are four different types of cutaneous melanoma; they 
are characterized by their growth patterns [Balch 85]. 
 
-7-  
The Clark melanocytic nevus, more commonly referred to as superficial spreading 
melanoma (SSM) accounts for approximately seventy percent of melanomas. SSM is the 
most common cutaneous melanoma, it normally originates in a preexisting nevus. It is 
less aggressive because it has two growth stages; it spreads in a radial direction through 
the epidermis before maturing, cloning and spreading depth-wise into the dermis. The 
more aggressive nodular melanoma (NM) accounts for fifteen to  thirty percent of 
melanomas. NM is the most aggressive and has the shortest clinical onset of the four 
types of melanoma Nodular melanoma is more aggressive because there is no radial 
phase; At the time of diagnosis NM has often reached the fully invasive stage because it 
immediately begins to grow depth-wise directly into the dermis layer of the skin making 
it harder to cure . Lentigo melana (LM), also known as Lentigonous malignant 
melanoma, makes up less than ten percent of melanomas. LM spreads at a slow rate 
along the surface of the skin; it has a varied benign stage anywhere between five to 
fifteen years. Acrolentiginous melanoma (ACM) makes up a smaller percentage than 
Lentigo melana. ACM unlike SSM and NM is more common to Asians and African 
Americans than Caucasians and it is normally located on the palms of the hands, nail bed, 
and soles of the feet. ACM makes up four to eight percent of cutaneous melanoma but it 
accounts for thirty-five to sixty percent of melanoma cases found in minorities. ACM is 
named for its arrangement of the melanocytes in a single file or “lentiginous” pattern. 
 
2.1.2 Staging 
Staging in melanoma and all other cancers is the process of assessing and designating 
extent and progression of disease. For the staging of melanoma, a four-stage system, 
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outlined in Table 2.1, was developed in the late 1970’s at the M. D. Anderson Cancer 
Center at the University of Texas [Gershenwald 98]. 
 
Table 2.1 The four-stage system for staging melanoma. 
Stage I Includes patients with primary melanoma only 
Stage II Includes patients with local recurrence (within 3cm of primary) 
Stage III 
   IIIA 
   IIIA 
   IIIAB 
Includes patients with regional disease 
   Intransit metastases 
   Nodal metastases 
   Intransit plus nodal metastases 
Stage IV 
   IVA 
   IVB 
Includes patients with distant disease 
   Cutaneous only 
   Any visceral site 
 
The flaw of this four staging system is that it did not include microstaging patients with 
primary melanoma, which is the largest patient group [Gershenwald 98].  Microstaging is 
an integral part of the prognosis of melanoma; it is based on the microscopic examination 
of the primary lesion; presented in 1962 by Petersen et al. [Gershenwald 98]. There are 
two methods that are used for characterizing microstaging in localized melanoma, the 
Clark level and Breslow thickness, the two methods together are part of the new tumor-
node-metastasis (TNM) staging system adopted by the American Joint Committee on 
Cancer (AJCC) [Eady 03, Zalaudak 03, AJCC]. A report was published in 1985 by Clark 
et al stating melanomas can develop in a stage specific manor [Kirkwood 98]. The Clark 
level developed by Clark et al in 1969, is based on the level of invasion, the local 
extension within the primary site, whereas the Breslow thickness developed in 1970, is a 
measure of tumor volume, how deep the tumor has extended from the granular layer to 
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the point of deepest penetration. The tumor has to be bisected in order for microstaging to 
occur. Once the primary lesion is removed pathology examines the lesion. Breslow 
thickness is measured in millimeters and predicts a statistical likelihood of a 5-year 
chance of survival (Table 2.2). The Clark’s level is not measured in millimeters but is 
described by level of invasion in the layers of the skin (Table 2.3). Clinical staging is also 
important, it is a noninvasive technique. Clinical staging consists of a complete doctor’s 
examination including; palpation of the lymph nodes for drainage, liver and spleen; a 
complete medical history, a complete examination of the skin and a blood test and chest 
x-ray (if patient is found to be in stage I). As the melanoma grows deeper into the skin it 
has the ability to move from the primary sites by either entering the bloodstream or the 
lymphatic system. After the melanoma has penetrated the lymph vessels within the layers 
of skin it travels through the fluid to the lymph nodes. The depth of the melanoma and the 
extent of nodal metastasis are key factors for determining the prognosis in melanoma 
[Gershenwald 98, Kim 02]. 
 
Table 2.2 Breslow system for the micro staging of melanoma 
 
Thickness in millimeters/inches 5-year survival rate 
≤ 0.75 mm(≈ 1/32 inch) 96% 
0.76-1.49 mm(≈ 1/32 to 1/16 inch) 87% 
1.5-2.49 mm (≈ 1/16 to 1/11 inch) 75% 
2.50-3.99 mm(≈ 1/11 to 1/8 inch) 66% 




Table 2.3 Clark staging by level involvement 
Stage I Tumor cells confined to the dermis layer 
Stage II Tumor cells penetrate into the papillary dermis 
Stage III Tumor cells completely fill the papillary dermis 
Stage IV Tumor cells enter the reticular dermis 
Stage V Tumor cells fill the dermis and enter the subcutaneous fat 
(According to the AJCC recommendations of combined staging of clinical 
and micro staging, lymph node involvement is to be designated stage II.) 
 
2.2 Breast Cancer 
2.2.1 Staging of Breast Cancer 
According to the National Cancer Institute breast cancer is the most common non-skin 
cancer and second to lung cancer as the leading cause of cancer related deaths in women 
today [ACS 03]. Evidence of the earliest cases of breast cancer is found in the Smith 
papyrus that dates back to the early Egyptians in 1600B.C. Although not called cancer, 
treatment of the ulcers or tumors included cauterization by a tool called “fire drill”. A 
major breakthrough in understanding cancer was made by Dr Henri Francois LeDran 
(1685-1770); he recognized that breast cancer could and did spread to the axillary lymph 
nodes; he was the first to associate a poor prognosis with lymph involvement. Much of 
the therapy and treatment today is based on his findings. In the mid 1800’s when 
surgeons began to keep detailed records, it was shown that women treated with 
mastectomy had a high rate of recurrence within an eight year period.  Over the last 
decade, the prognosis for breast cancer patients has improved, even more so for patients 
under the age of 50. The mortality rates have decreased by 2.3% per year from 1991 to 
2000 for all women diagnosed with breast cancer and 3.7% for women under the age of 
50 [ACS 03]. 
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The breast is made up of: fatty tissue, connective tissue between the fat and skin 
(Cooper’s ligament), 15-20 lobes, ducts that are connected to each lobe, a nipple and 
areaolas [Cook 96, Marchant 97]. The lobes contain alveoli, where milk is produced 
during lactation; the milk travels from the alveoli into the ducts and out of the nipple. The 
ducts resemble tree branches, the few collecting ducts in the nipple branch and end in 
terminal ductal lobular units. Blood vessels and lymphatic vessels are also located in the 
breast; the lymphatic vessels arise in the periductal spaces and drain to the axillary nodes 
[Marchant 97, Cook 96]. 
 
The most common types of breast cancer are ductal carcinoma and lobular carcinoma. 
Carcinoma is a cancer that develops in the epithelial tissues of the body. Invasive ductal 
carcinoma (IDC) spreads through the duct walls and invades the outside tissue; IDC 
develops from ductal carcinoma in situ, which develops in the milk ducts of the breast. 
DCIS is almost always curable since it is confined to the milk ducts Invasive lobular 
carcinoma (ILC) begins in the epithelial cell of the lobes, the milk glands of the breast 
[Cook 96]. Lobular carcinoma in situ is a noninfiltrating cancer; however, it is a marker 
for increased risk of developing breast cancer later. 
 
Early detection is one of the best ways to help fight against breast cancer. Women should 
visit their doctors regularly; between regular visits women can also perform monthly self-
breast exams. In addition to the self-breast exams women should be aware of some 
common symptoms: a lump on or near the breast or in the underarm area; a change in the 
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size or shape of the breast; a discharge in the nipple; or a change in the color or feel in the 
skin of the breast areola, or nipple [Cook 96]. 
 
2.2.2 Staging 
Staging for breast cancer and other solid tumors is based on the anatomical “TNM” 
system [Lohr 90]. This system classifies the tumor and local extent of tumor (T), the 
degree of nodal involvement (N), and absence or presence of metastasis (M) [Lohr 90, 
Marchant 97]. There are four basic stages (table 2.4) of breast cancer and the four stages 
are broken according to the TNM classification (table 2.5). 
 
Table 2.4 AJCC staging for breast cancer 
Stage Definition 
I Tumor <2 cm 
II Tumor 2-5 cm, Nodes 1-3 metastasis 
III Tumor >5, Nodes 4-9 lymph, apparent mammary nodes 
IV Tumor any size, Nodes any #, Metastasis to other organs 
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Table 2.5 The AJCC TNM staging for breast cancer 
“T” Primary Tumor 
TX Primary tumor can not be assessed 
Tis Carcinoma in situ 
T0 No evidence of primary tumor 
T1 Tumor is 2cm in greatest dimension 
T2 Tumor is >2 cm and < 5 cm 
T3 Tumor is> 5cm 
T4 Tumor is any size with direct extension to chest wall or skin  
“N” Regional lymph nodes 
NX Regional lymph nodes can not be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis to 1-3 axillary nodes or mammary with microscopic disease 
N1mi Micrometastasis >0.2 mm, ≤ 2.0 mm  
N2 Metastasis to 4-9 axillary nodes or apparent internal mammary nodes 
N3 Metastasis in 10+ axillary nodes  
“M” Distant metastasis 
MX Can not be assessed 
MO No distant metastasis 




Staging is part of the Diagnosis of cancer. The AJCC staging system is reviewed every 
few years. Staging for breast cancer determines if the cancer has metastasized, progressed 
into or past the lymph nodes. Metastatic disease is present in 5% or women at the initial 
diagnosis [winner, ellis]. In 2004 approximately 41,000 women died from metastatic 
breast cancer [winner, ellis]. Staging the cancer once it is confirmed will allow the doctor 
and patient to better plan a course for treatment. 
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3.1 Sentinel Lymph Nodes 
As indicated above, accurate staging of disease in a melanoma or breast cancer patient is 
critical for determination of accurate prognosis and of appropriate management of the 
patient’s disease. A significant component of the staging of melanoma and of the staging 
of breast cancer is determination of the extent of lymph node involvement—absence or 
presence of nodal involvement and number, location and extent of disease of involved 
lymph nodes. In patients with clinical evidence of nodal involvement, local regional node 
resection is often a component of staging. Such procedures usually result in the excision 
of multiple nodes and “routine” histological assessment of the excised nodes. In patients 
without clinical evidence of nodal involvement, such radical surgery seems to be 
unnecessary. Alternatives to radical resection biopsies are procedures known as sentinel 
lymph node (SLN) biopsies. Such are limited nodal resections in which only one to a few 
nodes are excised and assessed rather than the multiple nodes excised and assessed in 
radical resections. SLN biopsies are generally also procedures in which assessment of 
each excised node is much more extensive than it is in procedures involving  
 
The revised AJCC staging system is based on the fundamental idea that each melanoma, 
breast cancer or other neoplastic disease spreads systematically, beginning with an 
increase in the size of the neoplasm, and followed by local invasion and local nodal 
metastasis and finally transport by the circulatory and lymphatic systems to other organs 
and tissue [Kim 02]. For most cancers, a key prognostic factor is the number of lymph 
nodes with metastatic disease. Prior to the work of Morton et al.[Morton 92], assessment 
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of the status of lymph nodes was treated various ways from an elective lymph node 
dissection, to a wait and see approach [Statius 01]. There are two types of lymph node 
dissections, therapeutic lymph dissection and an elective lymph node dissection (ELND). 
In a therapeutic lymph node dissection once the lymph nodes are palpable or a biopsy is 
found to be positive, either by surgery or needle aspiration, the nodes are removed to 
alleviate pain and try to prevent spread. Therapeutic lymph dissection is management and 
care but an ELND is a preventative and prognostic measure. An ELND, FALD or a 
complete regional lymph node dissection removes a large number of lymph nodes from a 
certain area. Not all patients qualify to have this done, patients who do not have palpable 
nodes, and patients whose disease is thought to proceed to regional lymph nodes [Kenet 
98]. The morbidity resulting from ELND is the greatest drawback. The morbidity may 
consist of swelling, water retention, pain and/or lymphodema. The debate centered 
around ELND is, after having the surgery and accepting the great risk, there is no 
guarantee for benefits of survival [Tanis 01]. An alternative method to ELND which 
would not involve the associated morbidity is based on the systematic pattern idea, 
Sentinel lymph node resection (SLN) 
 
3.2 History to Present 
Morton et al. were the first to use a SLN technique for melanoma [Balch 85, Keshtgar 99, 
Nieweg 99, Zanzonico 00, Britten 99, Tsao 04]. The lymphatic system is a subsystem of 
the circulatory system. It has three functions it defends the body against foreign bodies 
such as viruses, bacteria or fungi by the flow of lymph (a bodily fluid) which circulates 
through lymphatic capillaries in the body collecting waste to deposit and filter out in the 
larger lymph nodes and it absorbs lipids from the intestine and carries them to the blood. 
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Lymph nodes are found through out the body: in the abdominal and chest cavities, in the 
neck, the limbs and where the limbs join the trunk of the body. The major groups of 
lymph nodes, the nodes of importance in melanoma and breast biopsies, lie in certain 
areas of the body: mastoid and sub occipital nodes of the head, cervical lymph nodes of 
the neck, axillary lymph nodes under the arms, inguinal lymph nodes of the groin area, 
and popliteal noded behind the knee. The sentinel lymph node is defined as the first 
lymph node to receive drainage from the primary tumor. Therefore, ideally if the tumor 
has metastasized to the lymph nodes they would be found in the sentinel nodes otherwise 
it has not yet metastasized and there is not a need for a full lymph node dissection. One of 
the first groups, Cabanas et al, to map the sentinel node using lymphangiography reported 
on the sentinel node in 1977 in a series of penile cancer surgical management cases 
[Alazraki 00]. SLN resection is used with many other types of cancers including breast, 
head and neck, and penile. Cabanas did not make use of current intraoperative techniques 
he simply used anatomical knowledge about lymph nodes and his preoperative lymphatic 
maping to intraoperatively palpate along the anticipated course of lymphatic drainage 
from the primary site to the first lymph node [Tanis 01, Alazraki 00]. This first node that 
he encountered he labeled, the SLN. Morton et al used more than just anatomical 
knowledge during surgery they made use of isosulphan blue dye. The concept of blue dye 
is that it flows through the lymphatic channels and stains the channels and lymph nodes. 
It is assumed that all sentinel nodes have been stained blue, therefore surgeons have to 
remove all the blue nodes to attain the SLNs. Radiotracers were first used in SLN 
localization by Krag et al in 1993 for melanoma surgeries [Knoll 89]. They used a 
technetium-99m (Tc-99m) labeled sulfur colloid particle and it was injected into the 
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patient prior to surgery and a hand-held gamma probe was used during surgery to detect 
the radiotracer. Currently blue dye, gamma probes, radioactive tracer and 
lymphoscintigraphy are used intraoperatively or preoperatively to assist SLN resection. 
SLN and these methods are used with other types of cancers. Twenty years prior to 
Cabanas reporting lymphatic drainage to the sentinel node from the penis, Gould 
performed a radical neck dissection a decision guided by a pathology report finding 
metastatic tumor in lymph node, suggesting a pattern for metastases [Baur-Subareoler, 
Tanis 01]. In the late 1970’s lymphoscintigraphy was used for the management in breast 
cancer patients although these were not SLN procedures. It wasn’t until the early 90’s 
that the SLN concept was applied to the management of breast cancer patients. Today 
SLN localization has been performed in colorectal cancers, gastrointestinal cancers, 
cervical, prostate cancers, head and neck, breast cancers and melanoma. 
 
3.3 General Technique 
Localization of SLNs is a component of standard practice in the management of most 
melanoma patients and many breast cancer patients with no clinical evidence of 
metastatic disease. Localization protocols vary in complexity and success. Those with the 
least components involve only intraoperative visualization of blue dye. At present, 
protocols with the most complexity involve preoperative radiotracer imaging, 
intraoperative gamma counting and intraoperative blue dye visualization. These protocols 
are more complex because there are more components and people to involve not because 
there is a higher level of difficulty or risk associated with the procedure. On the contrary, 
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the more complex procedure provides a smaller amount of risk and a higher level of 
success; success meaning the sentinel nodes were found and removed for pathology.  
 
3.3.1 Preoperative imaging 
Lymphoscintigraphy, the preoperative imaging was developed in the late 1950’s. It is 
performed by a nuclear medicine technologist. Preoperative imaging is important in 
melanoma because there are many drainage pathways from a tumor site and many times 
there is lymphatic drainage that is unexpected [Uren 03]. A radiotracer, Tc-99m sulfur 
colloid, is injected into the patient approximately five minutes before imaging begins. 
The ideal radiotracer in the United States the Tc-99m sulfur colloid is the only approved 
commercial product used for sentinel lymph node related lymphoscintigraphy and 
intraoperative probe guidance [Aarsvold 05]. The radiocolloid is made in two forms 
filtered and unfiltered. Filtered colloid particles use .22 µm filtration resulting in an 
injectate with particles that are smaller than 220 millimicra. Most particles are between 
100 millimicra and 220 millimicra. A comparative study of other colloids used in 
lymphoscintigraphy found that when colloids of sizes .220 µm to .100 µm were used the 
highest counts were recovered in the sentinel lymph nodes [Edreir 01]. Unfiltered Tc-
99m sulfur colloid has a wide range of particle sizes with an average of approximately 
305-340 millimicra and the largest is approximately 1000 millimicra. Sentinel node 
visualization using the different forms of radiocolloid was shown to be similar in a 
comparison study; although the visualization of lymphatic channels leading to the 




The radiotracer is administered by a subdermal or intradermal injection, which is an 
injection made right below the first layers of skin for melanoma and peritumoral, 
subdermal, or periareolar for breast cancer [Maza 03, Uren 03, Aarsvold 05]. The 
radiotracer is given at four to eight points around the tumor site. The activity and volume 
depends on the surgical team. The technologist massages the injection area to help 
disperse the radiotracer throughout the body. This procedure can take 30minutes to an 
hour but generally no longer than two hours. Dynamic images are acquired first, these 
allow the technologist to record the flow of radiotracer; and then static images are 
acquired. A large cobalt-57 flood source is used for transmission images to give the 
images a body outline for anatomical reference points. Before the technologist completes 
imaging, a mark is made on the body to reference the sentinel node(s).    
 
3.3.2 Intraoprative Imaging 
After the preoperative imaging is complete the patient is ready for surgery. The time of 
preoperative imaging to surgery depends on the relationship between the surgical and the 
nuclear medicine staff. The preoperative images can be done an hour prior to surgery or 
twenty-four hours prior to surgery although the surgery is usually on the same day as 
preoperative imaging, it is more convenient for the patient. The patient is prepped for 
surgery and put to sleep. After the patient is put to sleep the surgeon injects isosulfan blue 
dye. The blue dye is injected intradermally or subdermally [Aarsvold 05]. The surgeon 
then uses the surgical gamma probe and the mark made by the technologist to find the 
area to make the incision. The surgical gamma probe system used in surgery depends on 
the surgeon. There are many systems to choose from and the surgeon preference might be 
based on the tone and volume of the audio signal or the display for the counts or the ease 
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of use during surgery. The surgeon makes the incision and removes the blue and hot 
nodes found; sometimes they are just blue, sometimes they are just hot, sometimes they 
are secondary nodes and sometimes they are blue and hot. Once the nodes are removed 
they are sent to pathology. 
 
3.3.3 Pathology 
SLN resection has affected pathology in a positive way. Prior to SLN resections ten to 
thirty nodes were sent to pathology for examination; with SLN procedures there are 
usually one to three nodes and less commonly four sent to pathology. A more thorough 
examination can be done on a considerably smaller number of nodes. A histopathologic 
examination performed by pathologist includes mulisectioning and multiple analyses of 
the nodes. The multisectioning rather than bisecting of the nodes results much more 
tissue, 2 to 4 times as much, being examined increasing the detection of metastatic 
disease. An imunnohistochemical (IHC) analysis is also performed on the nodes that are 
sent to pathology, which also increases metastatic tumor detection compared with H&E 
staining. In breast cancer IHC analysis increase the percentage of micrometasis found in 
lymph node by an average of 20%, depending on the type of cancer [van Diest 99]. 
 
After the nodes are removed and sent to pathology the surgeon has completed the SLN 
resection. If results confirm there are positive nodes the surgeon may follow-up with a 
complete regional lymphadenectomy and chemotherapy [Statius 01]. The follow-up 
treatment depends on many other factors about the case as well as the results of the SLN 
resection although it usually involves examinations at 3-6 month intervals. .
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4.1 Gamma Detection in Sentinel Lymph Node Biopsies 
Two nuclear medicine techniques are used extensively in SLN biopsy procedures. These 
are gamma imaging and gamma counting. In most cases, what are detected are emissions 
of a Tc-99m labeled colloid, such as sulfur colloid. The techniques are tools for the 
detection and localization of possible SLNs. In some standard protocols preoperative 
gamma imaging is performed, in some preoperative gamma counting, in others 
intraoperative gamma counting, and in still others combinations of these techniques. 
Nuclear medicine techniques are not used in all SLN biopsy procedures; some 
practitioners use mostly visualization of blue dye. However, nuclear medicine techniques 
are used in the majority of SLN procedures. The focus of this thesis is intraoperative 
gamma imaging, specifically intraoperative gamma imaging with a novel relatively small 
FOV gamma camera. In this chapter, as foundation for understanding the technologies at 
play, we review briefly the conventional nuclear medicine technologies used in SLN 
biopsy procedures. We begin with a discussion of conventional gamma cameras and 
gamma counting probes and end the chapter with novel small and relatively small FOV 
gamma cameras. 
 
4.2 Conventional Gamma Cameras 
Gamma imaging is performed in SLN biopsy protocols as a means of detecting and 
locating possible SLNs. A radiopharmaceutical, such as Tc-99m labeled sulfur colloid, is 
injected near a melanoma or breast cancer  
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When preoperative lymphoscintigraphy is performed in SLN biopsy procedures, it is 
done so to observe and record lymphatic flow, more specifically, lymphatic flow from 
near the primary tumor to nodes considered possible SLNs. In most procedures, a Tc-
99m labeled colloid is injected into the patient and the imaging is performed using a large 
FOV gamma camera. An additional source is often used as a contrast source in order to 
obtain an anatomical outline for a point of reference. The gamma camera is based on the 
original design of 1958 by Hal Anger [Keshtgar 99, Knoll 89]. A single headed planar 
gamma camera is used for the preoperative imaging for SLN localization. The camera 
head is made of a lead collimator, a scintillation crystal and position-sensitive photo 
multiplier tubes (PSPMT). The gamma camera works by sensing two-dimensional 
coordinates of gamma ray photons as it interacts with the face of the camera [Keshtgar 
99, Knoll 89]. The photon is emitted from the patient and goes through led collimator, 
which is used to filter unwanted emissions. The collimator can be pinhole or hexagonal 
shape, and have a higher sensitivity or resolution or be multi-purpose. Once the photon 
has passed through the collimator it is absorbed by the scintillation crystal. The crystal is 
usually NaI(Tl) for many reasons such as cost, scatter properties, and longevity. The 
energy absorbed in the crystal is redistributed as light emissions, proportional to the 
energy, that is detected by the PSPMT. The PSPMT will generate an output pulse 
proportionate to the light that is interpreted by the computer system resulting in an X and 
Y position. That position is digitized and stored by the computer. The conventional 
gamma camera typically has a FOV ranging from 300mm in diameter for a single head 
camera to 400mm x 500mm for the contemporary rectangular head cameras. The 
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conventional gamma camera is only used for the preoperative images. Once the patient is 
in surgery the surgeon uses a gamma probe to assist further with localization. 
 
4.3 Counting Probes 
The use of a gamma probe in the operating room is similar to a Geiger-Mueller counter in 
that it functions only as a counter of radiation induced events [Krag 93]. The gamma 
probe is a non-imaging gamma detector usually containing a single detector. It has a 
crystal which can be NaI(Tl), CdTe, CsI(Tl), or CdZnTe is attached to a photomultiplier 
tube. The crystal ranges in size from 5 to 20mm in diameter [Dusi 01]. Although the most 
commonly used radioisotope for SLN localization is Tc-99, the system for a gamma 
probe is designed for an energy window that is capable of handling most commonly used 
radionuclides for intraoperative surgery (Table 4.1.). There are certain characteristics that 
are important to a gamma probe that is used intraoperatively for surgery [Tiourina 98];  
1. Sensitivity  
2. Resolution 
3. Ergonomics 
An intraoperative gamma probe should have a high signal to noise ratio. The ability of 
the probe to be able to detect nodes that may not have as much activity or that are behind 
fatty tissue is very important. The gamma probe should have adequate shielding to 
prevent background radiation and scatter from other tissue, organs and the injection site 
to interfere with localization. The minimum shielding for gamma probe used 
intraoperatively should be 3mm of tungsten or lead inside the probe itself this is to offer a 
factor of 1000 shielding against Tc-99 []. Side shielding is important to reduce the noise 
entering the side walls of the probe; this is important if the hot sentinel node is in the 
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proximity of the injection site. The software for the gamma probe should have the option 
of setting a window around the photopeak to help discriminate against scattered photons. 
The ergonomic details of the probe are important to the surgeon who has to use the probe. 
Weight, sound and display all affect the surgeons decision when choosing a gamma probe 
to use. Some surgeons rely solely on the sound when searching for the nodes and some 
surgeons rely on the sound and count display. The probe must also be easy to use in a 
sterile field.  
Table 4.1 Radionuclides commonly used for intraoperative surgery 
Radionuclide Energy (kev) 
of primary emission 
Tc-99 140 
I-123 159 





4.4 Intraoperative Gamma Cameras 
The small field-of-view (FOV) hand-held gamma camera is a more recent technology. 
The hand-held gamma camera is used to assist the surgeon to localize the sentinel nodes 
during surgery; it is used in conjunction with the surgical gamma probes and not meant to 
replace the probes. There are currently nine companies with small gamma cameras. Most 
of the cameras have a FOV that range from 2 cm x 2 cm to 5 cm x 5 cm or 10 cm x 10cm 
to 20 cm x 20 cm [Aarsvold 05]. Although the larger size cameras are still considered 
hand-held devices they are heavier, weighing no less then a kilogram; which makes them 
more difficult to maneuver during surgery. The technology is the same as the 
conventional gamma camera. It consists of camera face, scintillation crystal, collimators, 
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PSPMTs and a computer system. The scinitlation crystal varies depending on the 
designer; CsI(Na), NaI(Tl), CdZnTe, or CZT. With several groups working on the 
development of small gamma cameras, some camera designs are based on a single PMT 
and some are based on multiple PMTs [McElroy 00]. The size of the camera allows the 
user to place the camera face in closer proximity of the body then the larger conventional 
gamma camera. In breast cancer cases this is important because the camera can be placed 
directly against the breast at different angles, depending on the camera design [McElroy 
00]. Just as with the surgical gamma probe: sensitivity, spatial resolution and ergonomics 
are key characteristics to focus on when developing a system. Ergonomics is just as 
important as sensitivity and resolution. The surgeon must be able to handle a camera 
easily within the limitations of a sterile field. The main goal for the hand-held camera 
differs depending on the developer. Some developers want to design the camera to 
replace preoperative imaging others have a goal to develop a way to more quickly 








5.1 Investigation Overview 
In this and the next two chapters, we present descriptions, results, and discussions of the 
clinical investigation conducted in this research. Presentation of the material focuses on 
two studies. One involves melanoma patients; the other involves breast cancer patients. In 
this chapter, we present the methods and materials used in the two studies. Both studies 
were conducted only after all necessary approvals were obtained from the appropriate 
entities (institutional review boards, research and development committees, and radiation 
safety committees) at the VAMC—Atlanta, Emory University, and GA Tech. 
 
The general purpose of our clinical investigation was initial assessment of intraoperative 
imaging with a relatively small FOV gamma camera—in the context of SLN procedures. 
Over three years, 44 patients with melanoma or breast cancer with no clinical evidence of 
disease spread and scheduled for surgeries that included SLN procedures were consented 
and enrolled in our studies. All study subjects received all standard management and in 
addition 
 
The methods used for the SLN localization in our investigation are part of the standard 
protocol for surgeons at Emory University Hospital. The added procedure to the protocol 
was the use of a relatively small FOV gamma camera by the surgeon and scientific staff. 
Data from nineteen melanoma subjects and twenty-two breast cancer subjects were 
acquired for the characterization of a relatively small FOV gamma camera for the 
intraoperative use in SLN localization. The procedure for the patients included injections 
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of a radioisotope tracer, preoperative imaging with a conventional gamma camera, 
intraoperative injection of blue dye, intraoperative gamma counting, intraoperative 
imaging, resection of SLNs, a complete pathology report and follow up care. 
 
5.1.1 Description of Melanoma Study 
Nineteen subjects were enrolled in this study. The Emory protocol for melanoma 
surgeries with SLN procedures was followed, however, intraoperative imaging using a 
relatively small FOV gamma camera was added to the protocol. The Emory melanoma 
SLN protocol includes injection of Tc-99m sulfur colloid, preoperative gamma imaging 
and gamma counting, intraoperative gamma counting, injection and visualization of blue 
dye, resection of tissue and pathological examination of excised tissues. The addition of 
the intraoperative imaging did not alter significantly any aspects of the standard SLN 
procedure. 
 
5.1.2 Description of Breast Cancer Study 
The methods in study 2 included more details than in study 1. In addition to the two main 
tasks, the first task was divided into a more defined study where the subjects were 
divided into two branches. The first six subjects were preliminary cases that allowed the 
surgeon to get acclimated to the camera; the methods were similar to that of the 
melanoma cases. The procedure was different for the remaining sixteen subjects. They 
were split into two branches: the first branch was the probe/dye (PD) branch and the 
second was the camera/probe/dye (CPD) branch, the cases were randomly assigned to 
either branch. The two branches were compared to see what the differences were, if any, 
by adding the intraoperative gamma camera to the surgeries. In all cases, the surgeon was 
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blinded to preoperative images until the protocol was complete, unless she stated 
otherwise.  
 
5.2 Methods and Materials Common to Our Studies 
5.2.1 GammaCAM/OR 
The relatively small FOV (5in x 5in) (12.5cm x 12.5cm) gamma camera, a 
GammaCAM/OR (Gamma Medica Inc., Northridge, CA), used in this study was 
developed as a dedicated scintillation camera for breast and lymph node imaging 
[McElroy 00]. The camera was designed in response to the large bulky size of 
conventional gamma cameras and the limited spatial resolution [McElroy 00]. The 
GammaCAM/OR consists of the camera head mounted on a Leica surgical microscope 
arm with counter balance ability, mounted on a stand that contains the CPU, keyboard 
and monitor, Figure 5.1. The camera was used with a low-energy, high-resolution 
(LEHR) collimator (135 cpm/µCi). The camera head with out the collimator weighs 
fourteen pounds; with the collimator the weight is approximately twenty-two pounds. The 
camera consist of a 56 x 56 array of 2mm x 2mm NaI(Tl) crystals and a 5 x array of 1in x 
1in PSPMTs. During surgery the camera head and the surgical arm had to be covered 
with a surgical sheath to be used in the sterile field. 
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Figure 4.1. Gamma Medica Gamma CAM/OR system. The camera 
face is connected to a microscope arm which is connected to a stand. 
The camera has a 56 x 56 array  of 2mm NaI(Tl) crystals and a 5 x 5 






5.2.2 Camera Calibration 
On the day of each surgery the quality control (QC) checks were completed on the small 
FOV gamma camera, as with any piece of nuclear medicine equipment. A full calibration 
was done as needed, which was determined by doing routine QC check. A dose, 400µCi - 
650µCi, Tc99m was used to make a flood source; the dose was added to a plexiglass 
flood tank designed to fit on the face of the gamma camera. The isotope was obtained 
from the nuclear medicine department of the location of the camera, Emory University 
Hospital or VAMC-Atlanta nuclear medicine department. A syringe was used to deposit 




camera face. The QC was performed, if the results were acceptable, a standard deviation 
of 4.5% or less, the QC was not repeated, if the results were unacceptable then the QC 
was repeated or the system was calibrated. The camera was ready for surgery once the 
QC check was satisfactory 
 
5.2.3 Pathology 
All excised tissue was collected and carefully labeled. The specimens were sectioned by 
serial 5-µm sectioning, and were examined histopathologically with routine hematoxylin 
and eosin (H&E staining) and immunochemical staining (IHS) for S-100 protein and 
melanoma associated antigen HMB-45 [Carlson 03, Carlson 02]. Some tissue was 
removed as a single specimen but pathology found the single specimen contained 
multiple sentinel nodes, and some specimens were not recognized as sentinel nodes. 
Results of this procedure are sent immediately to the operating room as they can 
sometimes affect the surgical procedure. The lymph nodes were examined within thirty 
minutes of resection. If the frozen section H&E staining was positive, the patient was 
labeled positive for metastasis. If the frozen section was negative, further testing was 
done. The additional testing was IHC staining. The IHC analysis uses a pan-cytokeratin 
antibody to detect micrometastases. The slides were reviewed, and the size of each 
metastatic deposit, if any, in a SLN was measured with an ocular micrometer. 
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5.3 Melanoma Study Methods and Materials 
 
5.3.1 Subjects (melanoma) 
The subjects for the study were nineteen patients (9 male, 10 female) from a time period 
of three years, all scheduled for SLN resection surgery. A summary of characteristics of 
the subjects is located in table 5.1. The sites of the primary tumors were located: 7 trunk, 
2 head and neck and 10 extremities (5 upper, 5 lower). The mean age was 51.6 years.  
 
Table 5.1 Melanom Subject Characterization 
Subject Sex Age Location 
Me01 M 72 rt posterior/trunk 
Me02 F 42 abdomen/trunk 
Me03 F 55 rt upper arm/ extremities 
Me04 F 56 rt forearm/ extremities 
Me05 M 51 posterior neck/ head & neck 
Me06 M 71 rt forearm/ extremities 
Me07 F 39 lower back/ trunk 
Me08 F 31 lt leg/ extremities 
Me09 F 39 rt leg/ extremities 
Me10 F 41 lt thigh/ extremities 
Me11 M 46 lt arm/ extremities 
Me12 M 56 rt forearm/ extremities 
Me13 F 33 rt buttuck/ trunk 
Me14 M 72 rt leg/ extremities 
Me15 F 53 back shoulder/ trunk 
Me16 M 69 anterior neck/ head & neck 
Me17 M 50 lt foot/ extremeties 
Me18 M 44 lf shoulder/ trunk 
Me19 F 61 back/ trunk 
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5.3.2 Radiopharmaceutical injection (melanoma) 
On the day of surgery each subject was prepared for the preoperative imaging. The 
subjects lay down on the imaging table and were positioned by a nuclear medicine 
technologist. Each subject received 4 injections of 0.22-µm filtered 
99m
Tc sulfur colloid. 
The subjects received a total of 125µC to 240µC of injected dose. The intradermal 
injections were administered around the primary tumor site. Prior to the injections, all 
syringes were shaken to ensure the colloid was suspended in solution and well mixed. 
The area around the injection was massaged for one to five minutes after the final 
injection, to facilitate the flow of the radiopharmaceutical away from the injection site 
and into the lymphatic system. 
 
5.3.3 Preoperative imaging (melanoma) 
A GE 400 (GE Healthcare, Waukesha, WI) single-head gamma camera system with a 
low-energy all-purpose (LEAP) collimator (300 cpm/mCi) was used to do preoperative 
imaging of the subjects. Immediately following the massaging of the injection site, the 
image acquisition was started. The first set of images acquired recorded the dynamic flow 
of the radiotracer through the lymphatic channels and nodes. The dynamic images were 
taken in ten second frames for ten minutes. Multiple five minute static images up to an 
hour were acquired; in some patients a two hour injection delay image was acquired. The 
images acquired included anterior, lateral, and oblique views. Viewing of all three 
projections, results in a greater understanding of the positions of the nodes; it provides a 
three dimensional understanding of the location. A cobalt-57 flood source was placed on 
the opposite side of the subject from the camera, placing the subject between the camera 
and the source, to obtain a contour for an anatomical reference of the subject. After the 
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nodes were localized marks were placed anteriorly on the subject using a surgical marker. 
The marks provided the surgeon with an idea of the location to make the incision. 
 
5.3.4 Blue-dye injection (melanoma) 
Subjects were scheduled for surgery from two to eighteen hours after completion of the 
preoperative imaging. In the surgical suite after the subjects received anesthesia, they 
were given injections of isosulfan blue dye. This dye migrates into the lymphatic system 
and provides a possible means of visually identifying SLNs. Three to five injections with 
a total volume of 5 cc were given. After the dye was administered, the surgeon massaged 
the injected site for five minutes. 
 
5.3.5 Intraoperative gamma imaging/counting (melanoma) 
After the blue dye was administered, the scientist or the surgeon used the small FOV 
gamma camera to attempt to image the sentinel nodes. In the operating room the surgeon 
knew were the sentinel nodes were located because of the preoperative images and the 
mark on the subjects skin. In some surgeries the preincision image was taken before the 
sterile field was created. Once the area for surgery was prepared the camera head and arm 
had to be covered by a sterile sheath. In the latter surgeries a radioactive sterile marker 
was used to assist in positioning the camera head for the image acquisitions. The sterile 
marker was prepared prior to entering the surgical suite. A medical cotton swab was 
injected with a few microcuries of Tc-99m, the tip was then covered with medical tape to 
prevent contamination. Once the camera head was in place to acquire an image the 
radioactive marker would be placed in the field of view for a ten second acquisition. 
Using a sterile marker, the edges of the camera would be marked either on the patient 
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skin or on the sterile drapes. The pre-incision images were typically 3-minutes. After the 
images were taken the surgeon used the counting probe , Neoprobe 1000/1500 
(Neoprobe, Dublin, OH), which was also was covered with a sterile sheath, to confirm 
the location to make the incision(figure ). The surgeon also used the preoperative images 
and the marks on the subject’s skin for reference.  
 
Once the surgeon was confident he had located the area of interest, he made an incision. 
The counting probe was inserted into the incision and used to locate the node. After 
localizing the node, the surgeon removed the node and counted the excised tissue ex-
vivo. The ex-vivo count of the removed nodes was a ten second count done with the 
probe directed at the specimen such that the count rate was maximized. The probe was 
also placed in the excision bed to check for remaining activity. A post-excision image 
was acquired using the GammaCAM for duration no longer than three minutes. In the 
cases were the radioactive marker was used, it was placed on the mark made and using 
the marks for the camera edge the camera was put in place and the post excision image 
was taken. Excised tissue judged by the surgeon to contain SLNs was imaged for up to 5 
minutes to accurately quantify colloid uptake. Some specimens were sent to pathology 
for frozen-section analysis. The surgeon then completed the surgery with the stitching the 
excision. 
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5.4 Breast Cancer Study Methods and Materials 
5.5.1 Subjects (breast cancer) 
Twenty-two breast cancer patients were enrolled in this study. Six were enrolled in a 
short pre-study that provided us experience with the small FOV camera and an 
opportunity to identify and implement final refinements to the study protocol. Sixteen 
patients were enrolled in the primary study; the patients were randomly assigned to one 
of two branches. Eight patients were assigned to a branch that involved use of 
intraoperative gamma counting, gamma imaging, and blue-dye visualization—the 
probe/camera/dye (PCD) branch. Eight others were assigned to a branch that involved 
use of intraoperative gamma counting and blue-dye visualization only—the probe/dye 
(PD) branch. All subjects received preoperative imaging. Some of the subject 
characteristics are listed in Table 5.2. 
 
5.4.2 Radiopharmaceutical Injection (breast cancer) 
On the day of surgery each subject was prepared for the preoperative imaging. The 
subjects lay down on the imaging table and were positioned by a nuclear medicine 
technologist. Each subject received three injections, totaling 350 µCi of 0.22-µm filtered 
99mTc sulfur colloid. Two of the injections were peritumoral (Fig5.2.) and consisted of 
approximately 125 µCi in 1 ml. The third injection was subdermal (Fig5.2.) and consisted 
of approximately 250 µCi in 0.3 ml. Prior to the injections, all three syringes were shaken 
to ensure the colloid was suspended in solution and well mixed. The breast was massaged 
for one to five minutes after the third injection, to facilitate the flow of the 
radiopharmaceutical away from the injection site and into the lymphatic system. 
approximately 125 µCi in 1 ml. 
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Table 5.2 Breasty Cancer Subject Characterization 
Subject Sex Age Location Position 
Br01 F 78 lt 3:00 
Br02 F  rt 3:00 
Br03 F 54 lt 2:00 
Br04 F 40 rt 9:00 
Br05 F 64 lt 2:00 
Br06 F 58 rt 2:00 
Br07 F 47 lt 2:00 
Br08 F 52 rt 3:00 
Br09 F 58 lt 2:00 
Br10 F 80 rt 8:30 
Br11 F 77 rt 11:00 
Br12 F 66 rt 9:00 
Br13 F 65 lt 1:00 
Br14 F 69 lt 6:00 
Br15 F 53 rt 0:00 
Br16 F 46 rt 10:00 
Br17 F 41 rt 12:30 
Br18 F 43 rt 6:00 
Br19 F 42 rt 11:00 
Br20 F 67 lt 3:00 
Br21 F 81 rt 12:00 




   
   Peritumoral     Subdermal 
Figure. 5.2. Schematic of peritumoral injections. (R) Schematic of subdermal injection. 
Schematics were adapted from Keshtgar MRS, Waddington WA, Lakhani SR and Ell PJ. 
The Sentinel Node in Surgical Oncology, Berlin: Springer-Verlag, 1999, pp 51, 54. 
5.4.3 Preoperative imaging (breast cancer) 
 
 
A conventional single-head gamma camera, a GE 500 (GE Healthcare, Waukesha, WI), 
with a low-energy all-purpose (LEAP) collimator (300 cpm/mCi) was used to do 
preoperative imaging of the subjects (Figure 5.3). Immediately following the breast 
massage the image acquisition was started. Anterior, lateral and oblique views of 2 to 5 
minute duration were taken until radiotracer foci representing possible SLN were 
adequately visualized. The initial images acquired often helped reveal the dynamic flow 
of the radiotracer through the lymphatic channels and nodes. The images helped identify 
the order in which the nodes were visualized, which helps identity sentinel nodes from 
secondary nodes. A Co-57 source was placed on the opposite side of the subject from the 
camera to obtain a contour of the subjects body in the image. A single technologist, very 
experienced in SLN localization procedures, performed all preoperative imaging. 
Locations on the patients’ skin representing the anterior and lateral projections of each 
preoperatively detected focus were marked with UV fluorescent ink (A-800 blue 
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Figure 5.3.  Pre-operative imaging using a conventional single-head gamma camera 
(GE 500 w/ LEAP collimator).  The camera is positioned for acquisition of an anterior 
image.  A Co-57 sheet source, used as a transmission source to obtain body contours, 
is positioned under the imaging table.  The patient arm on the side of the involved 
breast is positioned as it will be during surgery. 
chlorine-resistant invisible readmission ink, UV Products, Upland CA). This allowed 
preoperative markings to be invisible during the procedures required for this blinded 




5.4.4 Blue-dye injection (breast cancer) 
Subjects were scheduled for surgery from two to eighteen hours after completion of the 
preoperative imaging. In the surgical suite after the subjects received anesthesia, they 
were given injections of isosulfan blue dye. This dye migrates into the lymphatic system 
and provides a possible means of visually identifying SLNs. Three to five injections with 
a total volume of 5 cc were given. After the dye was administered, the surgeon massaged 
the injected site for five minutes. 
 
5.4.5 Intraoperative gamma imaging/counting (breast cancer) 
After the blue dye was administered the surgeon then used the gamma probe to search the 
axillary and internal mammary regions of the subject. For the PD branch of the study, 
after the surgeon was confident she had completed the search for the sentinel nodes with 
the probe she was ready to make her incision. For the CPD branch of the study the 
surgeon used the small FOV gamma camera to image the sentinel nodes. Once the image 
acquisition was complete the surgeon was ready to make the incision. The UV light was 
used to see the marks made by the nuclear medicine technologist as a check for the 
surgeon. As part of the CPD branch the surgeon used the small FOV gamma camera and 
attempted to acquire images of the sentinel nodes. Each image acquisition was 
approximately two to three minutes long. The surgeon made the incision after the probe 
search or image acquisition. After making the incision the probe was used inside the 
excisional bed to locate the radioactive tissues. The surgeon then removed the radioactive 
tissue. The probe was used one last time inside the excisional bed to check for more 
radioactive tissue or lack of radioactivity and ex-vivo count of the tissue was also taken. 
If the subject was part o the CPD branch an image of the excisional bed was acquired 
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after the removal of radioactive nodes and a final image was acquired of the tissue that 
was deemed by the surgeon to be sentinel nodes. The duration of the excisional bed 
image was three minutes and the excised tissue was imaged for five minutes. 
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6.1 Melanoma Study Results 
The outcomes of this experiment are mostly qualitative not quantitative. Radioactive foci 
were visualized in 19/19 cases during preoperative imaging. The intraoperative imaging 
performed with the hand held gamma camera yielded visualization in 18/19 cases. In the 
first two melanoma surgeries tissue imaging was not performed therefore analysis on 
nodal uptake was performed on the latter 17 subjects, 103 exicised samples. Each data 
acquisition during surgery required at least two persons and added no more than thirty 
minutes to surgery. A maximum of six lymph nodes were removed from one patient and 
a minimum of one node was removed. The maximum uptake in an excised tissue was 
5386.85 nCi, 4.3% of the total injected activity; the minimum uptake in an excised tissue 
was 813 nCi, .08% of the total injected activity. The activity of radioisotope in each node 
removed is located in Table 6.1. A summary of each case is located in Appendix A. 
Three cases were found to have metastesis in the lymph nodes and were followed with 
regional lymphectomy. The following are the results of  two cases demonstrating findings 
of the camera.  
 
42 





camera activity focus / injected 
Me03-1 0 49 73 0.000 
Me03-2 5921 100 1134 0.522 
Me03-3 548 49 45 1.209 
Me03-4 423 72 40 1.059 
Me04-1 899 63 107 0.840 
Me04-2 2831 169 882 0.321 
Me04-3 1754 64 180 0.972 
Me05-1 939 144 363 0.259 
Me05-2 3662 121 434 0.844 
Me05-3 1397 81 200 0.698 
Me05-4 642 90 190 0.337 
Me05-5 1057 121 139 0.762 
Me05-6 879 156 195 0.451 
Me06-1 644 132 247 0.261 
Me07-1 5187 156 1269 0.409 
Me07-2 1978 132 339 0.583 
Me07-3 1879 168 1740 0.108 
Me08-1 24794 420 5387 0.460 
Me09-1 6711 196 1607 0.418 
Me09-2 13917 195 1706 0.816 
Me09-3 5940 208 858 0.693 
Me09-4 938 154 255 0.368 
Me09-5 694 144 81 0.852 
Me10-1 1132 272 466 0.243 
Me10-2 452 154 1139 0.040 
Me11-1 1143 208 180 0.634 
Me11-2 462 168 48 0.953 
Me12-1 4630 360 2180 0.212 
Me12-2 482 208 133 0.363 
Me13-1 3104 272 433 0.718 
Me14-1 1773 256 337 0.526 
Me15-1 1368 342 504 0.271 
Me15-2 1615 238 375 0.431 
Me15-3 7125 441 1019 0.699 
Me16-1 2118 342 223 0.951 
Me17-1 10817 621 3481 0.311 
Me18-1 16376 225 3191 0.513 
Me18-2 4234 195 1326 0.319 
Me18-3 1194 288 186 0.641 
Me18-4 3386 324 544 0.623 
Me19-1 844 240 110 0.766 
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6.1.1 Melanoma Example Case 1 
The first example is a fifty-six year old male with the primary lesion located on the right 
forearm. The images below (figure 6.1b-c) are intraoperative images taken with the small 
field-of-view gamma camera. The camera was successfully repositioned after the 
excision of the sentinel lymph nodes from the axilla using a radioactive marker. The 
successful repositioning of the camera after removing the lymph nodes allowed the 






Figure  . A 10 second image with a radioactive marker 
is taken post excision in order to reposition camera. 
Post-excision image taken shows node was removed. 
Figure 6.1a . Primary lesion 
is located on the right 
forarem. The camera was 
placed in the right axilla for 
imaging. 
Figure 6.1b. A 10 second image with a radioactive 
marker placed in the imaging field acquired using the 
small FOV camera. A preincision image with the 
camera in the same location.  
Figure 6.1c. A 10 second image with  radioactive 
marker is taken post excision in rder to reposition 
camera. A post-excision image taken show  activity 
was removed 
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6.1.2 Melanoma Example Case 2 
This case is a 51 year-old male with the primary lesion that was located on the distal 
dorsum of the left foot. The preoperative images are shown in figure 6.2b, with the two 
views lateral and anterior the surgeon can get a sense of depth of the node inside the 
tissue. The intraoperative images below also show an anterior and a lateral view, figure 
6.2c. Using the same radioactive marker technique intraoperatively the camera is 
positioned and repositioned in the same location for prexcision and postexicsion imaging; 
showing clearly the node removed postexicision and the residual activity. 
 
Figure 6.2a. Primary lesion is located on right 
foot. Imaging is done in inguinal axilla. 
 
anterior (15 min pi) 
Pelvis 
left lateral ( 20 min pi) 




Figure 6.2b. Preoperative images; anterior and lateral views of 
sentinel lymph node to be removed 
Figure 6.2c. Intraoperative images acquired with small FOV camera: Pre-incision lateral image 
of sentinel node, Anterior pre-incision image acquired showing multiple nodes located in the 




6.2 Breast Cancer Study Results 
The first six subjects were cases that allowed users to get acclimated to the small FOV 
gamma camera and develop a more defined comparison for the remaining cases, 
therefore some of the results are based on the later sixteen cases and some are based on 
the first six. In the first six cases the maximum uptake of activity for a single tissue 
sample was 12984 nCi, 4.5% percent of the injected activity; the minimum uptake for a 
single tissue sample was 29 nCi, .09% of the injected activity.  
In the latter sixteen cases preoperative imaging resulted in foci visualization in 16/16 
patients. Intraoperative external detection of the radioactive nodes using the gamma 
probe was accomplished in less than 4 minutes with a mean time equal to 1.5 minutes in 
15/16 patients; external detection was accomplished using the gamma camera in 6/8 
patients. The average time for completion of excision of nodes was 19 minutes for 
probe/dye and 28 minutes for camera/probe/dye. In one probe/dye case, review of the 
preoperative images prompted the surgeon to resume axillary dissection and remove one 
additional SLN. Two cases will be shown as an example.  
 
6.2.1 Breast Cancer Example Case 1 
Case 1 is a 49 year-old woman with lobular carcinoma on her right breast. The 
preoperative images demonstrate several foci of uptake, including foci located in axillary 
and internal mammary beds. In surgery, five radioactive tissue samples were excised 
from the axillary region; none were removed from the internal mammary region (Figure 
6.3). Intraoperative imaging showed that the foci in the area of interest had been 
completely removed from the nodal bed. Specimen imaging of the five excised samples 
(figure 6.4) demonstrated that nodal uptake ranged from 0.1% to 1.5% of the injected 
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dose (500 µCi).  At the time of imaging, several hours post injection, the specimens 
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Figure 6.3. Breast case 1. A 49 year old female with lobular carcinoma on her right 
breast. The preoperative image shows a foci in the axillary and internal mammary 
region. The small FOV camera was placed in the right axilla and internal mammary 
areas for the image acquisitions. The intraoperative images show the corresponding foci 
in the axillary and internal mammary regions. The axillary intraoperative images has pre 
and post excision images, showing the radioactive node was removed succesfully. The 
intraoperative post-lumpectomy images show the focus that the surgeon did not remove 
from the internal mammary region. 
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Table 6.2 Specimen intraoperative imaging 
Specimen ID Post-excision 




activity (%) (camera) 
1(SLNax) 7958 3740 1.46 
2(SLNax) 1262 376 0.15 
3(secLNax) 3190 459 0.18 
4(secLNax) 829 267 0.11 
5(secLNax) 2085 300 0.12 
Note that the hand-held probe counts do not accurately reflect the activity in the 
specimens as determined using the camera images and the camera’s sensitivity. The 
probe count rate is too sensitive to small changes in positioning relative to the sample,   
as well as to variations in sample activity distribution. 
 
Figure 6.4. Specimen Imaging. Five nodes were removed from the axillary region in 
case 1. The first three nodes were sentinel nodes, deemed by the surgeon and the last 
two lymph nodes were secondary axillary nodes. The images were a result of three 
minute acquisitions using the small FOV gamma camera. 
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6.2.2 Breast Cancer Example Case 2 
Case 2 is a 40 year-old female with an infiltrating ductal carcinoma on her right breast. 
Preoperative images demonstrate multiple foci of uptake (Figure C). Three channels of 
uptake are visible. In surgery, only one radioactive tissue sample was excised from the 
axillary region. Preoperative, intraoperative, and specimen imaging suggested the excised 
tissue contained more than one node. The specimen had two nodes: one 2 cm in diameter 
and one 4 cm in diameter. A large fraction, approximately 4.5% of the injected dose, was 
absorbed and retained by the nodes; at the time of imaging almost four hours post 
injection the node contained approximately 13,000 nCi of Tc-99m. The remaining node, 

























Figure 6.5. Breast case 2 The preoperative image shows a large foci located in the 
right axilla as well as visable channels from the injection site to the foci. The small 
FOV camera was placed in the right axilla for image acquisisition. Only one focus 
was removed and secondary foci are left in place. 
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7.1 General Discussion 
In this study the investigation of the use of a small FOV gamma camera, A Gamma 
Medica GammaCAM/OR, for intraoperative detection and localization of SLNs in 
melanoma and breast cancer cases. The essential goals in a SLN protocol are detection 
and localization of all the SLNs. The SLNs have to be detected in order to be resected 
and biopsied,  
 
7.2 Melanoma Study Discussion 
The preoperative imaging resulted in visualization of foci in all 19 cases. An experienced 
nuclear medicine technologist in the Nuclear Medicine department of Emory University 
Hospital performed the preoperative imaging. The intraoperative imaging performed 
using the small FOV gamma camera yielded visualization in all but one of the nineteen 
cases. The one case that the intraoperative camera did not yield a focus was a more 
difficult case due to the attenuation from a larger body mass and breast tissue, the activity 
decay due to a five hour time difference, and the shine through from the injection site. 
After making the incision the surgeon had to search further and deeper to locate the node 
for removal. This case demonstrated the limitations of having a smaller FOV camera and 
working in the operating; the technologist was only able to visualize the node 
preoperatively after an hour of imaging and six different camera positions. If there was a 
case that the surgeon had to survey the lymphatic regions in a case without having 
preoperative imaging, using a camera with a FOV smaller then the one used in this 
investigation would not be beneficial and would be very time consuming. 
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The details of a SLN protocol make a significant difference. The important details related 
to the research performed were: 1. The surgeon is a very skilled and experienced, 2. The 
nuclear medicine technologist were experienced, 3. There was a good working 
relationship between the surgeon and nuclear medicine staff, and 4. The surgeon used 
quality preoperative images. After experiencing the nineteen melanoma cases it was not 
evident that under the listed circumstances a small FOV gamma camera would add value 
to such a surgical protocol. However as a result of participating in the nineteen surgeries 
the protocol for using the intraoperative camera was improved upon. One of the 
limitations of having a small FOV camera is the lack of anatomical reference. It was 
evident that camera could be successfully repositioned, after excision and node removal, 
in order to obtain an accurate assessment of the excisional bed. Accurate repositioning of 
the camera allowed the surgeon to visualize any residual activity remaining in the 
excisional bed, assuring the surgeon that the foci had been removed. As shown in 
melanoma case 2 the radioactive marker was placed in the preexcision image and the 
postexcision image giving users an image of residual activity. It should be noted because 
of movement from cutting, cauterizing and stretching the tissue will not be exactly as it 
was prior to incision. 
Imaging the tissue ex vivo gave additional information for research purposes; there was 
no direct benefit to the subjects or the surgery. The gamma camera gave more 
information than using the gamma probe ex-vivo. The information obtained about the 
nodes could be used for future work on intraoperative imaging and radioisotopes in the 
operating room. The surgeon does not know exactly how many nodes has been resected 
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until the results from pathology has returned. The surgeon only knows how many tissue 
samples have been excised only pathology can accurately determine the number of nodes 
in a tissue sample. 
 
7.3 Breast Cancer Study Discussion 
The procedures for the first six breast cancer cases were similar to the melanoma 
procedures. In the latter sixteen cases the study was more defined and the cases were split 
into two branches. The preoperative imaging for all the cases was performed by a skilled 
nuclear medicine technologist in the Nuclear Medicine department of the VAMC-
Atlanta. In the preoperative imaging, foci was visualized in all the cases, 6/6 and 16/16.  
Although the blue dye was used all the radioactive nodes resected were not blue and 
some blue nodes resected were not “hot”; those nodes that were not “hot” were sent to 
pathology as secondary nodes. In the latter sixteen cases, the subjects were split into two 
defined branches; the C/P/D branch and the P/D branch. The important details that were 
constant in both branches of this study were: 1. A skilled surgeon performed all the 
surgeries, 2.Quality preoperative imaging was performed by a skilled technologist, and 3. 
A gamma probe and blue dye were used intraoperatively in all surgeries. As the surgeon 
was blinded to all preoperative imaging, a mean time of less1.5 minutes was needed to 
localize the radioactive foci externally using the gamma probe. Intraoperative preincision 
counting using the gamma probe was successful in 15/16 cases. Intraoperative external 
detection using the gamma camera was accomplished in 6/8 cases. In one case, which 
was missed by both the probe and camera it was difficult because the node did not have a 
substantial uptake; in the preoperative images the focus did not have many counts and 
there was less activity due to decay during surgery which did not commence until five 
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hours late; in the other case the injection site was too close to the node. The surgeon was 
skilled using the gamma probe, however there is always uncertainty of how many nodes 
there are, having the preoperative images greatly reduces the uncertainty. The 
intraoperative camera did not add value to the procedure prior to incision and the excision 
of the foci under the specific circumstances. The surgeon did mention in one case that the 
camera help confirm that the radioactive nodes had been removed after performing post-
excision image. It is possible the small FOV gamma camera could have added value in 
confirming the removal of radioactivity from the excisional beds. It is also possible that 
under other circumstances the camera could have added value in other aspects. 
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Intraoperative imaging in SLN protocols was the primary topic of this investigation. 
Specifically, we investigated the use of a relatively small FOV (12.5cm x 12.5cm) 
gamma camera, a Gamma Medica GammaCAM/OR, for intraoperative imaging in 
melanoma and breast cancer SLN biopsy procedures. The investigation included 41 
subjects, 19 melanoma and 22 breast cancer patients. Intraoperative imaging was 
performed in 33 of the surgical procedures. The reported investigation is the most 
extensive clinical evaluation of the use of intraoperative imaging with a small or 
relatively small FOV gamma camera yet performed. 
 
8.2 Conclusions 
8.2.1 Melanoma Study Conclusions 
In the melanoma study, we investigated the incorporation of intraoperative imaging into a 
well-established melanoma SLN biopsy procedure. The imaging incorporated was 
performed using the GammaCAM/OR. Nineteen patients were enrolled in the study. The 
primary conclusion of the study is intraoperative imaging with a relatively small FOV 
gamma camera can be incorporated into melanoma SLN procedures. However, the 
addition of a relatively small camera to a well-established protocol that includes; 
preoperative nuclear medicine imaging, intraoperative gamma counting, intraoperative 
blue-dye visualization, and surgical procedures performed by a surgeon with extensive 
experience in melanoma SLN procedures, is of limited added value as regards the 
detection and localization of possible SLNs. 
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In a few cases in this study, the surgeon noted that post-excision intraoperative images of 
some excisional beds helped him to more rapidly conclude that all radioactive foci that 
were possible SLNs had been excised. There is the possibility that in these cases there 
was added value through increased surgeon confidence that the resection procedure was 
complete and fully successful. Our study was not designed to assess that specific form of 
possible added value. Additional investigations specifically designed to assess such may 
be useful. Our experience however, does suggest that preoperative imaging is a critical 
feature of melanoma SLN procedures and should be a component of all melanoma SLN 
procedures. We suspect that the addition of intraoperative imaging to a procedure that 
includes preoperative imaging will almost always have limited added value as regards the 
localization of possible SLNs. 
 
We note, to be clear, the results of this study are limited to the specific context of our 
investigation. It is not prudent to extrapolate our results beyond the context of this study. 
For example, assessment of the value of the addition of intraoperative imaging to a 
melanoma SLN procedure in which preoperative imaging is not included or in which 
intraoperative imaging is done with a large FOV camera rather than a relatively small one 
or in which the surgeon has limited experienced or is even a trainee has not been 
addressed by this investigation. Intraoperative imaging may have value in one or more of 
these contexts; our investigation was not designed to address these contexts directly. 
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8.2.2 Breast Cancer Study Conclusions 
Two studies were performed with breast cancer patients as subjects. The first was a small 
study in which intraoperative imaging with the GammaCAM/OR was simply added to a 
well-established breast cancer SLN biopsy procedure. Six patients were enrolled in this 
preliminary study. The results of this first study were used to finalize specifications for 
our primary breast cancer study and to provide the investigative and surgical teams 
opportunities to become familiar with the technology and protocols of the investigation. 
 
The primary breast cancer study was a two-branch study in which subjects were 
randomly assigned to one of the two branches. Sixteen subjects, eight in each branch, 
were enrolled in this study. In one branch, we used a well-established breast cancer SLN 
procedure which included intraoperative gamma counting with a gamma counting probe. 
In the other branch, we used a modified version of the same SLN procedure. The 
modification to the SLN procedure was the addition of intraoperative imaging with the 
relatively small FOV gamma camera. One other modification of the well-established 
procedure was added to both branches of the study. Preoperative images were acquired as 
part of the established procedure, but the surgeon was blinded to the results of the 
imaging until all study aspects of the surgical procedure were complete. 
 
The main conclusion of the primary breast cancer study is a surgeon with extensive 
experience in breast cancer SLN procedures may find limited added value in the addition 
of intraoperative imaging to a well-established SLN procedure that does not include 
preoperative imaging. However, a definitive assessment of the nature and amount of 
added value that can result from the use of intraoperative imaging requires additional 
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investigation. Our experience suggests factors that should be well defined in such 
investigations include: detailed specification of the other detection/localization 
techniques included in a procedure, skills/experience of the participating surgeons, the 
size of the FOV and the sensitivity of the camera to be used, and the ease of use of the 
imaging system, particularly the ease of positioning of the camera. 
 
Many surgeons use preoperative imaging, but many do not. Our results suggest that 
including intraoperative imaging in procedures that do not include preoperative imaging 
will prove useful in some cases, but likely only in a few cases if the procedures are 
performed by a very experienced surgeon. It is expected that there would be minimal 
added value from adding intraoperative imaging to a procedure that includes high-quality 
preoperative imaging and an experienced surgeon would be minimal. 
 
Similarly with the results of the melanoma study, the results of this study should not be 
extrapolated beyond the context of this investigation. Parameters that appear critical to 
the results of this study include: a very experienced surgeon; blinding the surgeon to the 
results of preoperative imaging—thus, the absence of preoperative images; intraoperative 
imaging with a relatively small FOV gamma camera as opposed to a camera with a small 
or large FOV; and technical aspects of the imaging system, e.g., camera sensitivity and 
ease/non-ease of camera positioning. 
 
An overall conclusion from our studies is SLN procedures which include preoperative 
imaging that are modified to include intraoperative imaging using a relatively small FOV 
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gamma camera; is unlikely to produce a measurable improvement on SLN detection 
rates; however, SLN procedures performed using protocols that do not include 
preoperative imaging may be enhanced if a surgeon has access to the visual information 
that intraoperative imaging can provide. 
 
8.3 Observations 
Most research suggests that melanoma and breast cancer SLN protocols that include 
preoperative nuclear medicine imaging will result in higher SLN localization rates than 
those that do not. However, for various reasons, it is not always possible to obtain high 
quality preoperative images, and. thus, not all such SLN protocols include preoperative 
nuclear medicine imaging. Investigation of the use of intraoperative imaging in protocols 
that do not include preoperative imaging should continue as intraoperative imaging in 
some form may yet prove significant in some contexts. 
 
The patient studies reported above were not designed to investigate specifics about 
technology requirements. However, experience gained in the investigation leads us to the 
following observations. Camera sensitivity is much more important than camera 
resolution for the task of intraoperative localization of SLNs in a melanoma or breast 
cancer patient. Accurate camera positioning and repositioning together with ease of 
positioning and repositioning are important if intraoperative imaging is to be performed 
and surgical resources are to be used efficiently and effectively. A camera’s FOV should 
quite likely be larger than that which we used as the nominal areas that need to be 
searched for possible SLNs are larger than the FOV of the camera we used. 
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Camera sensitivity is important because the simple task of imaging a focus representing 
significant radioactive uptake is straightforward. What is not straightforward is the 
imaging of a focus of small uptake (uptake of only 100s or even 10s of nanocuries). 
Some SLNs have very little uptake, yet intraoperative imaging protocols must be such 
that low uptake nodes are routinely detected and localized. Ease of camera motion is also 
important. An intraoperative camera system should be such that its camera can be moved 
effortlessly and simultaneously positioned accurately at any location within the entire 
sterile field. If this is not the case, surgical effort and surgical time are increased, often 
significantly. SLNs are found in many locations relative to a tumor, particularly in 
melanoma patients, but also in breast cancer patients. The size of a camera’s FOV 
remains an issue. For SLN procedures for melanoma and breast cancer and for many 
other cancers, our experience suggests that intraoperative imaging might be more 
effective if cameras with moderately large or large FOVs were used. Such cameras would 
in one image acquire the information a relatively small FOV system only acquires with 
two, three, or even four images. 
 
8.4 Future Directions 
Our investigation focused on the use of a relatively small FOV gamma camera for 
intraoperative localization of SLNs in patients with melanoma or breast cancer and used 
procedure parameters of specific well-established SLN biopsy procedures. As indicated 
above, there are many variants of our investigation that might be pursued. A possible 
direction of future investigation would be one in which studies similar to those we have 
performed would be conducted. The studies would enroll melanoma and breast cancer 
patients as we did, but the investigations would differ from ours in that they would 
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involve different gamma camera technologies and/or they would use surgeons with 
different levels of experience than those in our investigation. 
 
An interesting direction of research would be one designed to develop SLN protocols for 
cancers for which preoperative nuclear medicine imaging is difficult at best—difficult 
because appropriate preoperative injection of a radiopharmaceutical is difficult. Consider 
lung and colorectal cancers, for example. A few SLN procedures have been conducted on 
such patients, but no SLN procedure for routine use for patients with such cancers exists. 
Radiotracer injections around lung and colorectal cancers, if attempted preoperatively, 
would likely need to be performed under CT guidance—an exercise that would be quite 
difficult in many cases. A possible alternative to preoperative injection and imaging, if 
intraoperative imaging is a viable option, is intraoperative injection of a 
radiopharmaceutical after surgical opening followed by intraoperative imaging. Our 
efforts have demonstrated intraoperative imaging for SLN localization is feasible if 
radiotracer injections are administered preoperatively. Development of intraoperative 
SLN procedures for cancers such as lung and colorectal require development of practical 
(time limited) intraoperative procedures for SLN localization. The work we have reported 
provides a solid foundation for expectation that successful SLN protocols can be 
developed for cancers such as lung and colorectal even if such protocols require 
intraoperative injection and imaging of radiopharmaceuticals. However, our investigation 







5x5 Patient: ME01 
Date of Study: 12/20/01 
Patient Initials: AB 
Patient History: 
 Sex: M 
 Age: 72 
 Location of Tumor/Lesions: Right Posterior Trunk 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: 




Sample ID Indicator Post-ex count OR Img Activity Location 
1(SLN) Hot/blue 12328 NA Right axilla 
2(SLN) Hot 731 NA Left axilla 
3(SLN) Hot 1659 NA Left axilla 
 
Pathology: Hot SN#1 (0/1) non-blue, Hot SN#2 (0/1) non-blue, Hot SN #3 (0/1) non-blue 
 
Comments/Discussion:  The lesion is located on the right posterior of the trunk (Left mid peri dorsal). 
Patient was injected 08:55 with 0.136 mCi. and surgery started 14:30. There were no positive nodes found 
out of a total of 3. Margin resected measures 7.6cm long by 3.3cm wide by 2.5cm deep, Scar in center 
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TIFF name:    preinc rlat  Interfile name:    ME01_1 
Image duration:    180 sec          Start time:    13:57:35 
 
 
TIFF name:    preinc llat  Interfile name:    ME01_1 
Image duration:    180 sec          Start time:    14:28:20 
 
 
TIFF name:    postex rlat  Interfile name:    ME01_2 
Image duration:    300 sec          Start time:    15:00:22 
 
 
TIFF name:    postex llat  Interfile name:    ME01_2 





5x5 Patient: ME02 
Date of Study: 01/03/02 
Patient Initials: MK 
Patient History: 
 Sex: F 
 Age: 42 
Location of Tumor/Lesions: Abdomen to the left of midline below the umbilicus 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: 




Sample ID Indicators Post-ex counts OR img activity Location  
1(SLN) Hot/blue 5561 NA Left axilla 
2(SLN) Hot 2430 NA Left axilla 
3(SLN) Hot/blue 10138 NA Left inguinal 
4(SLN) Hot/blue 1917 NA Lateral inguinal 
5(SLN) Hot 3758 NA Left inguinal 
 
 
Pathology: Hot SN #1 (0/3)no mention of blue, node size ranges 0.8-1.5 cm; Hot SN #2 (0/1) non-blue, 
node and tissue measures 1.5 x 1.0 x 0.5cm; Hot SN #3 (0/1) blue, node and tissue measures 2.0 x 1.0 x 0.5 
cm, node diameter measures 1.7 cm; Hot SN #4 (0/1) blue, node and tissue measures 3.2 x 1.5 x 0.5cm, 
node measures 1.0 cm in diameter;  Hot SN #5 (0/1) non-blue, node and tissue measures 3.2 x 1.5 x 0.5 cm  
and node measures 1.0 cm in diameter.  
 
 
Comments/Discussion: The lesion is located on the left of the abdomen below the umbilical area (Left peri-
umbilical melanoma).  The patient was injected at 10:20 with 0.159 mCi of Tc-sulfur colliod. Surgery began 
at 16:00. There were no positive nodes found out of a total of 7 nodes. The margin resected measured 5.0 x 
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TIFF name:    ant pelvis1  Interfile name:    ME02_1 
Image duration:    180 sec          Start time:    15:44:15 
 
 
TIFF name:    lao45 ax  Interfile name:    ME02_2 
Image duration:    120 sec          Start time:    15:49:01 
 
 
TIFF name:    ant pelvis2  Interfile name:    ME02_3 
Image duration:    240 sec          Start time:    15:53:27 
 
Attempt to get injection site into picture… 
TIFF name: lao45 ax postex    Interfile name:    ME02_4 









TIFF name: ant pelvis postex   Interfile name:    ME02_5 
Image duration:    300 sec          Start time:    17:31:02 
 
Deep focus (#4) not excised (see lateral preop image) 
ME03 
72 
5x5 Patient: ME03 
Date of Study: 01/03/02 
Patient Initials: PR 
Patient History: 
 Sex: F 
 Age: 55 
 Location of Tumor/Lesions: Right upper arm 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: 




Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(NonSLN) Blue No counts 71 Right axilla 
2(SLN) Blue/hot 5921 1118 Right axilla 
3(SLN) Hot 548 45 Right axilla 
4(SLN) Hot 423 42 Right axilla 
 
 
Pathology: Hot SN #1(0/1) blue, node and adipose tissue measures 1.9 x 1.4 x 0.5 cm; Hot SN #2 (0/1) 
non-blue, node and tissue measures 2.5 x 1.0 x 0.5 cm; Hot SN #3 (0/1) non-blue, 1.0 x 0.5 x 0.5 cm. 
 
Comments/Discussion: The lesion is located on the right upper arm(right upper extremity). The patient was 
injected with 0.167mCi of Tc99m sulfur colloid at 12:10. Surgery began at 17:55. There were zero positive 
nodes found out of 3 SN. The resected tissue has a raised scar 0.9 x 0.8cm in size. There are no significant 
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TIFF name:    rao30 ax  Interfile name:    ME03_4 
Image duration:    300 sec          Start time:    18:01:19 
 
 
TIFF name:    non-sn  Interfile name:    ME03_5 
Image duration:    300 sec          Start time:    18:17:09 
 
Surgeon thought no probe counts, but… 
TIFF name:    node1  Interfile name:    ME03_5 
Image duration:    240 sec          Start time:    18:23:14 
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TIFF name:    rao30 ax postex    Interfile name:    ME03_2 
Image duration:    300 sec                 Start time:    18:42:08 
 
 
TIFF name:    node3  Interfile name:    ME03_3 





5x5 Patient: Date of Study: ME04 
Patient Initials: TH 
Patient History: 
 Sex: F 
 Age: 56 
 Location of Tumor/Lesions: Right forearm 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 400 Emory nuclear med staff 
 OR Images: 5 x 5 gamma camera 
 
Tissue Resected: 
 Neoprobe  
Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(SLN) Hot 899 118 Right axilla 
 2(SLN) Hot 2831 849 Right axilla 
3(SLN) Hot 1754 183 Right axilla 
 
 
Pathology: Hot SN #1 (0/1) no mention of blue dye, node and adipose tissue measures 2.5 x 1.5 x 1.0 cm; 
Hot SN #2 (0/1) no mention of blue dye, node and tissue measures 1.5 x 1.5 x 0.5 cm; Hot SN #3 (0/1) no 
mention of  blue dye, node and tissue measures 1.0 x 0.8 x 0.5 cm. 
 
Comments/Discussion: The lesion is located on the right forearm (mid dorsal right forearm). The patient 
was injected at 9:05 with 0.152mCi of Tc99m sulfur colloid. Surgery began at 16:35 hours. There were no 
positive nodes of 3 sent for pathology. The scar found on the excised tissue was 0.7cm in size. There was 
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TIFF name:    rao ax  Interfile name:    ME04_1 
Image duration:    180 sec          Start time:    16:06:02 
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TIFF name:    rao ax postex    Interfile name:    ME04_3 
Image duration:    180 sec             Start time:    17:15:46 
 
Camera positioning altered from that in “rao ax”…  but we can’t tell 
that here. 
TIFF name:    node3   Interfile name:    ME04_4 





5x5 Patient: ME05  
Date of Study: 01/28/02 
Patient Initials: PW 
Patient History:  
 Sex: M 
 Age: 51 
 Location of Tumor/Lesions: Base of posterior neck, slightly left of midline 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 400 Emory nuclear med staff 




Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(SLN) Hot 939 358 Left neck 
2(SLN) Hot 3662 438 Left neck 
3(SLN) Hot 1397 209 Left neck 
4(SLN) Hot 642 195 Left Medial 
5(SLN) Hot 1057 139 Left Medial 
6(SLN) Hot  879 187 Right neck 
 
Pathology: There was no mention of blue dye for any of the lymph nodes examined. Hot SN #1(0/1), node 
and tissue measures 2.5 x 1.2 x 0.5 cm; Hot SN #2 (0/1), node measures 0.3 cm in greatest dimension; Hot 
SN #3 (0/1), tissue and node measures 1.5 x 0.7 x 0.5 cm; Hot SN #4 (0/1), tissue and node measures 1.7 x 
0.7 x 0.6 cm; Hot SN #5 (0/1), tissue and node measures 0.9 x 0.5 x 0.5 cm; Hot SN #6 (0/1), tissue and 
node measures 2.5 x 1.5 x 1 cm . 
 
 
Comments/Discussion: The lesion was located on the posterior base of the neck slightly left of the mid 
line. The patient was injected with 0.162 mCi of Tc99m sulfur colloid at the 10:45 hour. Surgery began at 
19:00 hours. There were no positive nodes found in any of 6 nodes examined. The scar centered in the wide 
excised tissue measured 2 x0.1cm. This patient also had a previous biopsy on back of lower left thigh. There 
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5x5 Patient: ME06 
Date of Study: 06/05/03 
Patient Initials: RJ  
Patient History: Skin right forearm melanoma. 
 Sex: Male 
 Age: 71 
 Location of Tumor/Lesions: Right forearm  
Breslow thickness 2.50 mm  
Clark level at least IV 
 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 400 Emory nuclear med staff 




Preop focus  Sample ID Indicator Post-ex count OR Img Activity Location 
1 1 Hot 644 247 Right axilla 
 
Pathology: No mention of blue dye. Hot SN #1 (0/1), node measures 3.0 x 1.5 x 0.9 cm. 
 
 
Comments/ Discussion: The melanoma is located on the right forearm (proximal radial right forearm at 
elbow), stage II and was measured to be 2.58mm by outside report. The patient was injected with 0.233 mCi 
of Tc99m sulfur colloid at 9:00. Surgery began at 12:30. The sentinel node was not positive and it measured 
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5x5 Patient: ME07 
Date of Study: 06/05/03 
Patient Initials:  LC 
Patient History:  
 Sex: F 
 Age: 39 
 Location of Tumor/Lesions: Left lower back 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 400 Emory nuclear med staff 





Sample ID Indicator Post-ex count OR Img Activity Location 
 1                     Hot 5187 1269 Left axilla-lateral 
2 Hot 1978 339 Left axilla –mid 
3 Hot 2219 1740 Axilla-medial 
 
Pathology: Hot SN #1 (0/1), non-blue, node & tissue measures 3.7 x 2.9 x 0.5cm; Hot SN #2 (0/1), non-
blue, node & tissue measures 2.7 x 2.6 x 0.7cm; Hot SN #3 (0/1), non-blue, node & tissue measures 3.0 x 
3.0 x 0.7. 
 
Comments/Discussion: The melanoma is located on the lower left lateral back and measures 0.95mm (by 
outside report). The patient was injected at 10:45 with 0.244 mCi of radiocolloid. Surgery began at 15:45 
hours. There were no positive nodes out of a total of 3 sentinel nodes. There was nothing significant to note 
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5x5 Patient: Me08  
Date of Study: 06/09/03 
Patient Initials:  SM 
Patient History:  
 Sex: F 
 Age: 31 
 Location of Tumor/Lesions:  Melanoma, left lower leg. nodular growth pattern 
  Breslow Thickness: 1.95mm 
  Clark Level: at least IV  
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 400 Emory nuclear med staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/Blue 24794 5387 Left inguenal femerol 
 
Pathology: Hot SN #1 (0/1) non-blue, measures 4.4 x 3.0 x 1.0cm. 
 
Comments/Discussion: The melanoma is located on the lower left leg and measures 2.0mm (by outside 
report). The patient was injected at 8:50 with 0.194mCi of Tc99m sulfur colloid. Surgery began at 11:35 



















TIFF name: excised node Interfile name:    ME08_3 
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5x5 Patient: Me09 
Date of Study: 06/09/03 
Patient Initials:  JL 
Patient History: 2years ago Dr. noticed and said watch, 2 mths ago started changing colors. 
 Sex: F 
 Age: 39 
 Location of Tumor/Lesions: melanoma right lower leg. Superficial spreading pattern.  
  Breslow Thickness: 0.9mm 
  Clark Level: III-IV 
Surgeon: Murray 
Images/Data of study:   
 Preop Images: GE 400 Emory nuclear med staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/Blue 6711 1607 Rt Inguenal Femoral  
2 Hot/Blue 13917 1706 Mid-Inguenal, lat-rt 
3 Hot/Blue 5940 858 Mid-inguenal medial 
4 Hot 938 255 Mid Supra Inguenal  
5 Hot 694 81 Mid Supra Inguenal 
 
Pathology: Hot SN #1 (0/2) blue, sentinel node measures 2.6cm in greatest dimension; Hot SN #2 (0/1), 
blue, sentinel node measures 2.6cm in greatest dimension; Hot SN #3 (0/1), non-blue, sentinel node 
measures 1.5cm in greatest dimension; Hot SN #4 (0/1), non-blue, SN measures 1.3cm in greatest 
dimension; Hot SN #5 (0/1), non-blue, SN measures 1.4cm in greatest dimension.  
 
Comments/Discussion: The melanoma is located on the right lateral calf and measures 0.95mm (by outside 
report). The patient was injected at 10:30 with 0.216mCi of Tc99m sulfur colloid. Surgery began at 14:05 
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5x5 Patient: Me10 
Date of Study: 06/12/03 
Patient Initials:  VS 
Patient History: Patient first noticed in 03/2003. Mother had skin cancer on face. 
  Sex: F 
 Age: 41 
 Location of Tumor/Lesions: Melanoma lower left thigh, superficial spreading pattern. Ulceration 
absent. Initially excised and measured at .99mm 
  Breslow Thickness: 1.5mm 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 400 Emory nuclear med staff 




Preop focus  Sample ID Indicator Post-ex count OR Img Activity Location 
1 1 Hot/Blue 1132 466 Lt  fossa, anterior 
2 2 Hot/Blue 452 1139 Fossa poster Lt side 
 
Pathology: Hot SN #1 (0/1) blue, node measures 2.5 x 1.5 x 0.7cm; Hot SN #2 (0/1) blue, node measures 
0.7 x 0.5 x0.5. 
 
Comments/Discussion: The melanoma is located on the left thigh (left mid posterior thigh) and measures 
0.99mm (by outside report). The patient was injected at 8:55 with 0.198mCi of Tc99m sulfur colloid. 
Surgery began at 12:22 hours. There were 0 nodes positive out of a total of 2 nodes. There was nothing 




















TIFF name:    preincision  Interfile name:    ME10_1 
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5x5 Patient: ME11 
Date of Study: 07/10/03 
Patient Initials: DB  
Patient History: first occurrence of skin cancer 
 Sex: M 
 Age: 46  
 Location of Tumor/Lesions: left lower arm just below elbow 
  Breslow Thickness: 1.45mm 
  Clark Level: at least level IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/Blue 1143 180 Subscapular fossa ant 
2 Hot/Blue 462 48 Subscapular fossa post 
 
Pathology: Hot SN #1 (0/1) blue, node & tissue measures 3.0 x 1.7 x 0.9cm; Hot SN #2 (0/1) blue, node 
measures 2.1 x 2.5 x1.0. 
 
Comments/Discussion: The melanoma is located on the left arm behind elbow (posterior lateral left 
forearm) and measures 1.35mm (by outside report). The patient was injected at 8:50 with 0.198mCi of 
Tc99m sulfur colloid. Surgery began at 11:40 hours. There were 0 nodes positive out of a total of 2 nodes. 
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5x5 Patient: ME12 
Date of Study: 07/10/03 
Patient Initials: PP  
Patient History: Brother has melanoma, father basal cell carcinoma 
 Sex: M 
 Age: 56 
 Location of Tumor/Lesions: Melanoma on right forearm 
  Breslow Thickness: 2.25mm 
  Clark Level: level IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/blue 4630 2180 Upper level 1 rtaxilla 
2 Hot 482 133 Upper level 1 rtaxilla 
(only deeper) 
 
Pathology: Hot SN #1 (0/1) blue, node measures 4.0 x 2.0 x 1.0cm; Hot SN #2 (0/1) blue, node measures 
2.0 x 1.0 x 0.8cm. 
 
Comments/Discussion: The melanoma is located on the right forearm (proximal dorsal right forearm) and 
measures 2.5mm. The patient was injected at 11:00 with 0.186mCi of Tc99m sulfur colloid. Surgery began 
at 16:30 hours. There were 0 nodes positive out of a total of 2 nodes. There was nothing significant noted 
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5x5 Patient: ME13 
Date of Study: 07/17/03 
Patient Initials: AM 
Patient History: No history of skin cancer 
 Sex: F 
 Age: 33 
 Location of Tumor/Lesions: right buttock 
  Breslow Thickness: 1.75 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/blue 3104 433 Rt lateral inguenal 
 
Pathology: SN #1 (1/1), node measures 1.1 x 0.6 x 0.3 cm. 
 
 
Comments/ Discussion: The melanoma is located on the right buttock was measured to be 1.75mm by 
outside report . The patient was injected with 0.212 mCi of Tc99m sulfur colloid at 8:30. Surgery began at 
13:00 hours. . The sentinel node is positive by IHC S-100 and negative by IHC HMB45. A re-examination 
of right inguinal tissue was completed a month later. Two additional samples were sent for pathology. There 
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5x5 Patient: ME14 
Date of Study: 07/24/03 
Patient Initials: LS  
Patient History: Previously biopsied 
 Sex: M 
 Age: 72 
 Location of Tumor/Lesions: Right Lower leg  
  Breslow Thickness: 2.1mm 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/Blue 1773 337 Rt inguenal femoral 
 
Pathology: Hot SN #1 (1/1) blue, node & fibrofatty tissue measures 3.0 x 2.5 x 1.5 cm. 
 
 
Comments/ Discussion: The melanoma is located on the right lower inner leg (proximal posteromedial 
right leg) was measured to be 2.1mm by outside report and 2.0mm by Emory findings. The patient was 
injected with 0.203 mCi of Tc99m sulfur colloid at 9:00. Surgery began at 12:00 . The sentinel node is 
positive for clusters and single cells of metastatic melanoma by both IHC S-100 and IHC HMB45 but 
negative by H&E stain. Because there was presence of metastatic melanoma in the two IHC the node was 
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5x5 Patient: Me15 
Date of Study: 07/24/03 
Patient Initials:   
Patient History: Basal cell carcinoma removed last year from back in same area. 
 Sex: F 
 Age:  
 Location of Tumor/Lesions:  Upper left on back near shoulder blade 
  Breslow Thickness:  
  Clark Level:  
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot/Blue 1368 504 Lt nape of neck 
2 Hot/Blue 1615 375 Subscapular fossa lt axilla 
3 Hot 7125 1019 Deep subscapular fossa 
 
Pathology: Hot SN #1 (0/1) blue, node measures 0.6 x 0.6 x 0.8 cm; Hot SN #2 (0/2) blue, largest node 
measures 3.1 x 1.3 x 0.4 cm; Hot SN #3 (0/4), non-blue, largest node measure 1.1 x 0.8 x 1.3 cm. 
 
 
Comments/ Discussion: The melanoma is located  (left mid paradorsal area) was measured to be 2.0 mm 
by outside report and 2.4 mm by Emory. The patient was injected with 0.196 mCi of Tc99m sulfur colloid at 
10:18. Surgery began at 15:00 . Out of the three nodes submitted for pathology there were a total of 7 






 LTDORSAL 15MIN LTLAT 20MIN  
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5x5 Patient: ME16 
Date of Study:  07/31/03 
Patient Initials: RD 
Patient History: Previous melanoma on back 4 years ago, approx 1.1mm axillary nodes negative 
 Sex:  M 
 Age:  69 
 Location of Tumor/Lesions: right anterior neck 
  Breslow Thickness: 1.3-1.62mm 
  Clark Level:  IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot 2118 223 Submental mid line 
 
Pathology: First Case: No mention of blue dye. Hot SN #1 (0/2), nodes measure 2.0 x 1.5 x 0.4 cm and 0.5 
x 0.5 x 0.3 cm; Hot SN #2 (0/1), node measures 1.0 x 1.0 x 0.5 cm. Second Case 4 years later: Hot SN #1 
(0/1), non-blue, node and fibrofatty tissue measures 1.8 x 0.9 x 0.8 cm. 
 
 
Comments/ Discussion: Initially the subject had intermediate thick melanoma located at the right mid-
paraspinal area measured to be 1.45mm. There were no nodes found to be positive and there was no spread 
to the excisional margins. Four years later subject returned for wide excisional margin of thin melanoma 
measured 1.3 mm located mid and anterior right neck. The patient was injected with 0.192 mCi of Tc99m 
sulfur colloid at 8:50. Surgery began at 12:09. The 1 sentinel node submitted for pathology and was 
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5x5 Patient: ME17 
Date of Study: 07/31/03 
Patient Initials: PR 
Patient History: Lesion was noted 3-4 months ago, it was new & dark, developed cellolitus in the biopsy. 
 Sex: M 
 Age: 50  
 Location of Tumor/Lesions: Left foot anterior near toes. 
  Breslow Thickness: 2.5mm 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot 10,817 3484 Lt inguenal femoral 
 
Pathology: No mention of blue dye. Hot SN #1 (1/2), nodes measure 2.1 x 1.9 x 1.0 cm and 1.7 x 1.3 x 0.6 
cm. 
 
Comments/ Discussion: The melanoma is located on the left foot  (dorsum left foot) was measured to be 
2.4 mm by outside report and 2.5 mm by Emory. The patient was injected with 0.171 mCi of Tc99m sulfur 
colloid at 10:44. Surgery began at 16:00. Out of the 1 node submitted for pathology there were a total of 2 
sentinel nodes and there was 1 positive node. Because of the positive node the subject returned for a full 






















TIFF name: preincison sterile  Interfile name:ME17_2 
Image duration:    300 sec          Start time:    16:10:10 
 
 
TIFF name: preincision ant   Interfile name: ME17_1a 
Image duration:    180 sec          Start time:    15:08:06 
 
 
TIFF name: preincision ltlat   Interfile name:ME17_1b 
Image duration:    180 sec          Start time:    15:13:29 
 
 
TIFF name: postexcision sterile  Interfile name:ME17_3 








TIFF name: excised node    Interfile name:ME17_4 






5x5 Patient: ME18 
Date of Study: 08/04/03 
Patient Initials: PR 
Patient History: Noted mole in 2002, recently noted to be increasing in size, changing color a bleeding 
easily 
 Sex: M 
 Age: 44 
 Location of Tumor/Lesions: left shoulder 
  Breslow Thickness: 2.35mm 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot 16376 3191 Upper post level 1 lt axilla 
2 Hot 4234 1326 Subscapular fossa 
3 Hot 1194 186 Medial pectoral nerve 
4 Hot 3386 544 Pectoral nerve at apex of lt 
axilla 
 
Pathology: Hot SN #1 (1/1), non- blue, node measures 1.1 x 1.1 x 0.6 cm; Hot SN #2 (0/1), non-blue, node 
measures 1.4 x 1.0 x 0.6 cm; Hot SN #3 (0/1), non-blue, node measure 1.3 x 0.6 x 0.4 cm; Hot SN #4 (1/1), 
non-blue, node measures 1.1 x 1.0 x 0.4 cm. 
 
 
Comments/ Discussion: The melanoma is located left shoulder (posterior cap of left shoulder) and was 
measured to be 2.35 mm by outside report and 2.35 mm by Emory. The patient was injected with 0.231 mCi 
of Tc99m sulfur colloid at 8:38. Surgery began at - . Out of the 4 nodes submitted for pathology there was 1 
positive node. As a result of the positive node the subject returned two months later for a more complete 






 ANT 10MIN LTLATAX 20MIN  
 














TIFF name: excised node 1_2  Interfile name: ME18_3 
Image duration:    300 sec          Start time:    15:06:51 
 
 
TIFF name: preincision sterile  Interfile name: ME18_1 
Image duration:    180 sec          Start time:    10:29:54 
 
 
TIFF name: postexcision    Interfile name: ME18_2 
Image duration:    180 sec          Start time:    15:32:48 
 
 
TIFF name: excised node_3   Interfile name: ME18_4 









TIFF name: excised_4   Interfile name:ME18_5 





5x5 Patient: ME19 
Date of Study: 08/04/03 
Patient Initials:   
Patient History: noticed lesion on her back about 3-4 months ago 
 Sex: F 
 Age: 61 
 Location of Tumor/Lesions:  On back 
  Breslow Thickness:  2.8mm 
  Clark Level: IV 
Surgeon: Murray 
Images/Data of study:  
 Preop Images: GE 500 Emory nuclear medicine staff 




Sample ID Indicator Post-ex count OR Img Activity Location 
1 Hot 844 110 mid level 1 rt axilla 
 
Pathology: Hot SN #1 (1/6), non-blue, largest node measures 1.7 x 1.0 x 1.5 cm;  
 
Comments/ Discussion: The melanoma is located  (right mid interscapula thoracic region) was measured to 
be 2.8 mm by Emory. The patient was injected with 0.231 mCi of Tc99m sulfur colloid at 10:21. Surgery 
began at 5:30 pm . Out of the one node submitted for pathology there were a total of 6 sentinel nodes and 
there was 1 positive node. As a result of the positive node the subject returned for a completion of  
therapeutic right axillary lymphadectomy.   There was nothing significant to note about this case. A total of 






 ANT 10MIN ANT W_PULLED BREAST  
 




















TIFF name: preincision nonsterile  Interfile name: ME19_1 
Image duration:    180 sec          Start time:    18:33:19 
 
 
TIFF name: postexcision   Interfile name:ME19_4 
Image duration:    180 sec          Start time:    19:19:12 
 
 
TIFF name:injection site   Interfile name: ME19_2 
Image duration:    70sec          Start time:    17:19:48 
 
 
TIFF name: injection site postexcision Interfile name:ME19_3 








TIFF name: excised node   Interfile name:ME19_5 










5x5 Patient: BR01  
Date of Study: 12/20/01 
Patient Initials: MC 
Patient History:  
 Sex: F 
 Age: 78 
 Location of Tumor/Lesion: Left breast @3:00. 
Surgeon: Murray 
Images/Data of study: 
 Preop Images: GE 500 by Sandi 




Sample ID Indicators Post-ex count OR img activity Location 
1(SLN) Hot/blue 215 88 Left axilla 
 
 







LAO 15MIN      LTLAT AX 20MIN 
 
 















       
 
       
 
 
TIFF name:    preinc llat  Interfile name:    BR01_1 
Image duration:    180 sec          Start time:    16:30:24 
 
First OR attempt; we don’t seem to have positioned camera correctly! 
TIFF name:    node   Interfile name:    BR01_2 





5x5 Patient: BR02   
Date of Study: 01/05/02 
Patient Initials: MO 
Patient History: 
 Sex: F 
 Age:  
 Location of Tumor/Lesions: Right breast @ 3:00. Cup size: A 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE 500 by Sandi 
 OR Images: 5 x 5 gamma camera 
Tissue Resected: 
 C-Trak  
 
Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(SLN) Hot/blue 7958 3735 Right axilla 
2(SLN) Hot 1262 404 Right axilla 
3(SecLN) Hot/blue 3190 461 Right axilla 
4(SecLN) Hot/blue 829 268 Right axilla 


















       
 
       
 
       
 
       
 
TIFF name:    lao30 ax  Interfile name:    BR02_1 
Image duration:    120 sec          Start time:    14:20:21 
 
 
TIFF name:    ant im  Interfile name:    BR02_2 
Image duration:    120 sec          Start time:    14:23:42 
 
 
TIFF name:    nodes1and2  Interfile name:    BR02_3 
Image duration:    180 sec          Start time:    14:45:21 
 
 
TIFF name:    node3  Interfile name:    BR02_4 





       
 
       
 
       
 
       
 
TIFF name:    node4  Interfile name:    BR02_4 
Image duration:    180 sec          Start time:    14:54:23 
 
 
TIFF name:    node5  Interfile name:    BR02_4 
Image duration:    180 sec          Start time:    14:57:48 
 
 
TIFF name:    lao45 ax postex     Interfile name:    BR02_5 
Image duration:    180 sec                 Start time:    15:02:32 
 
 
TIFF name:    ant im postlump1    Interfile name:    BR02_6 
Image duration:    144 sec                  Start time:    15:43:24 
 




       
 
       
 
TIFF name:    ant im postlump2    Interfile name:    BR02_6 
Image duration:    120 sec                  Start time:    15:46:05 
 
Repositioning… 
TIFF name:    node im     Interfile name:    BR02_7 
Image duration:    180 sec          Start time:    16:06:13 
 
Where did it go??? 
BR03 
152 
5x5 Patient: BR03 
Date of Study: 01/16/02 
Patient Initials: IL 
Patient History: 
 Sex: F  
 Age: 54 
 Location of Tumor/Lesions: Left breast @ 2:00. Cup size:C 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE 500 by Sandi 
 OR Images: 5 x 5 gamma camera 
Tissue Resected: 
 C-Trak  
Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(SLN) Hot 4913 720 Axillary 
2(SLN) Hot 1850 182 Axillary 
3(SLN) Hot  362 72 Axillary 
4(SLN) Hot 4501 511 Axillary 
5(SLN) Hot 3003 325 Axillary 
6(Axcont)  No counts 111 Axillary 
7(SLN) Hot 1045 523 Left SN 
















       
 
       
 
       
 
       
 
TIFF name:    lao45 ax  Interfile name:    BR03_1 
Image duration:    120 sec          Start time:    14:24:11 
 
 
TIFF name:    ant ax   Interfile name:    BR03_2 
Image duration:    120 sec          Start time:    14:29:07 
 
 
TIFF name:    nodes1-4  Interfile name:    BR03_3 
Image duration:    120 sec          Start time:    15:08:49 
 
 
TIFF name:    node5   Interfile name:    BR03_4 





       
 
       
 
       
 
       
 
TIFF name:    node6  Interfile name:    BR03_5 
Image duration:    119 sec          Start time:    15:27:24 
 
 
TIFF name:    node7   Interfile name:    BR03_6 
Image duration:    120 sec          Start time:    15:25:53 
 
 
TIFF name:    lao45 ax postex      Interfile name:    BR03_7 
Image duration:    120 sec          Start time:    15:29:39 
 
Camera position (angle wrt body) changed from “lao45 ax”… 
TIFF name:    ant ax postex       Interfile name:    BR03_8 





5x5 Patient: BR04  
Date of Study: 01/23/02 
Patient Initials: JS 
Patient History: 
 Sex: F 
 Age: 40 
 Location of Tumor/Lesions: Right breast @ 9:00. Cup size:D 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE 500 by Sandi  
 OR Images: 5 x 5 gamma camera 
Tissue Resected: 
 C-trak  
 
Sample ID Indicators Post-ex Counts OR Image Activity Location 


















       
 
       
 
       
 
       
 
TIFF name:    lao45 ax wind1  Interfile name:    BR04_1 
Image duration:    180 sec                 Start time:    11:08:03 
 
Two nodes closely spaced can be seen with this display windowing. 
TIFF name:    lao45 ax wind2  Interfile name:    BR04_1 
Image duration:    180 sec                 Start time: 11:08:03 
 
Windowing display to reveal smaller-activity foci obscures above-
referenced structure. 
TIFF name:    ant ax wind1  Interfile name:    BR04_1 
Image duration:    180 sec                 Start time:    11:12:31 
 
 
TIFF name:    ant ax wind2  Interfile name:    BR04_1 





       
 
       
 
       
 
       
 
TIFF name:    nodes    Interfile name:    BR04_2 
Image duration:    120 sec                 Start time:    11:46:25 
 
 
TIFF name:    ant ax postex bed  Interfile name:    BR04_2 
Image duration:    120 sec                 Start time: 11:51:04 
 
Windowed to show very low levels of activity. 
TIFF name:    [aborted]    Interfile name:    BR04_2 
Image duration:    31 sec                 Start time:    11:53:58 
 
 
TIFF name:    ant ax postex sec  Interfile name:    BR04_2 
Image duration:    120 sec                 Start time: 11:55:54 
 
Camera repositioned to show secondary node not excised. 
BR05 
162 
5x5 Patient: BR05 
Date of Study: 02/25/02 
Patient Initials: MS 
Patient History: 
 Sex: F 
 Age:  
 Location of Tumor/Lesions: Left breast @ 2:00. Cup size: D 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE 500 by Sandi 
 OR Images: 5 x 5 gamma camera 
Tissue Resected: 
 C-Trak  
Sample ID Indicators Post-ex Counts OR Image Activity Location 
1(SLN) Hot 1300 186 Axillary 
2(SLN) Hot 272 24 Axillary 



















       
 
       
 
       
 
       
 
TIFF name:    lao45 ax1  Interfile name:    BR05_preinc 
Image duration:    180 sec          Start time:    14:06:13 
 
 
TIFF name:    lao45 ax2  Interfile name:    BR05_preinc 
Image duration:    180 sec          Start time:    14:11:11 
 
 
TIFF name:    nodes   Interfile name:    BR05_nodes 
Image duration:    180 sec          Start time:    14:38:17 
 
 
TIFF name:    nodes sep  Interfile name:    BR05_nodes 
Image duration:    180 sec          Start time:    14:43:08 
 




       
 
 
TIFF name:    lao45 ax postex  Interfile name:    BR05_postex 





5x5 Patient: BR06  
Date of Study: 02/25/02 
Patient Initials: JM 
Patient History: 
 Sex: F 
 Age: 58 
 Location of Tumor/Lesions: Right breast @ 2:00. Cup size: C 
Surgeon: Styblo 
Images/Data of study:  GE 500 by Sandi 
 Preop Images:  5 x5 gamma camera 
 OR Images: 
Tissue Resected: 
 C-Trak  





1(SLN) Hot/blue 1894 2124 Axillary 
2(SecLN) Hot/blue 386 105 axillary 
 
 













       
 
       
 
       
 
       
 
TIFF name:    node1  Interfile name:    BR06_nodes 
Image duration:    180 sec          Start time:    16:31:13 
 
 
TIFF name:    lao45 ax1  Interfile name:    BR06_preinc 
Image duration:    150 sec          Start time:    15:49:30 
 
 
TIFF name:    lao45 ax2  Interfile name:    BR06_preinc 
Image duration:    150 sec          Start time:    15:53:32 
 
 
TIFF name:    lao45 ax3  Interfile name:    BR06_preinc 





       
 
       
 
TIFF name:    node2  Interfile name:    BR01_nodes 
Image duration:    180 sec          Start time:    16:37:54 
 
 
TIFF name:    lao ax postex         Interfile name:    BR06_postex 






5x5 Patient: BR07 
Date of Study: 11/04/02 
Patient Initials: RM 
Patient History: Both grandmother’s and aunt died from breast cancer. 
 Sex: F 
 Age: 47 
 Location of Tumor/Lesion:.left breast @ 2:00 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE500 and 5x5 camera by Sandi 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot/Blue 4153 NA Lft axilla 
2 Hot/Blue 850 NA Lft axilla 
3 Hot/Blue 1328 NA Lft axilla 
4(axill node) Hot/Blue 301 NA Lft axilla 















       
 






TIFF name: slnsurvey_1 ANT  Interfile name: BR07_1 
Image duration:    300 sec          Start time:    11:37:08 
 
 
TIFF name: slnsurvey_3 ANT   Interfile name:BR01_3 
Image duration:    300 sec          Start time:    11:57:34 
 
 
TIFF name: slnsurvey_2 left  Interfile name: BR07_2 
Image duration:    300 sec          Start time:    11:49:45 
 
 
TIFF name: slnsurvey_4 ANT  Interfile name: BR07_4 






5x5 Patient: BR08 
Date of Study: 11/19/02 
Patient Initials: BB 
Patient History:  
 Sex: F 
 Age:  
 Location of Tumor/Lesion:.right breast  
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE500 and 5x5 camera by Sandi 




Sample ID Indicators Post-ex count OR img activity Location 


















       
 








Timing for Dr. Styblo 
10:58 Probe start 
11:00 axillary count, pre-inc 692 
11:06 axillary incision 
11:09 mass #1 excised  
11:12 incision probe 






TIFF name: slnsurvey_1 ANT  Interfile name: BR08_1 
Image duration:    200 sec          Start time:    09:02:42 
 
 
TIFF name: slnsurvey_2 RAO  Interfile name: BR08_2 






5x5 Patient: BR09 
Date of Study: 03/12/03 
Patient Initials: MH 
Patient History: 58 year old nonpalpable. Excisional biopsy 2/7/03 
 Sex: F 
 Age: 58 
 Location of Tumor/Lesion:.left breast @ 2:00 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE500 and 5x5 camera by Sandi 




Sample ID Indicators Post-ex count OR img activity Location 























       
 






TIFF name: preincision_1  Interfile name: BR09 
Image duration:  90 sec          Start time:    11:20:14 
 
 
TIFF name: preincision_2  Interfile name: BR09 
Image duration:    300sec          Start time:   11:23:22 
 
 
TIFF name: postexcision  Interfile name: BR09 
Image duration:    300sec          Start time: 11:44:29 
 
 
TIFF name: postexcision_2  Interfile name: BR09 







TIFF name: contents  Interfile name: BR09 










Timing for Dr. Styblo 
11:21-Start probe search 
11:24-First count background 
11:25-Counting node ,Dificulties positioning 
11:31-Acquired image 1, attempted to count where probe counts were detected . Used q-tip tracer to locate 




11:52-Counting excised nodes, Image 3:node1 
12:05-Image 4:node 2 





5x5 Patient: Br10 
Date of Study: 03/17/03 
Patient Initials: BM 
Patient History: Partial mastectomy in right breast, sentinel node palpable by patient & doctor 
 Sex: F 
 Age: 80 
 Location of Tumor/Lesion: Right breast 8:30, ≈1.7cm 
Surgeon: Styblo 
Images/Data of study: 
 Preop Images: GE500 by Sandi 





Sample ID Indicators Post-ex count OR img activity Location 
2 Hot/Blue 889 NA Rt axilla 




















5x5 Patient: Br11 
Date of Study: 03/18/03 
Patient Initials: JM  
Patient History: Palpable node found in right breast during annual physical, FNA one month later, Ex 
biopsy three days later (2/25/03) 
 Sex: F 
 Age: 77 
 Location of Tumor/Lesion: Right breast @ 11:00 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by Sandi 




Sample ID Indicators Post-ex count OR img activity Location 





Comments/Discussion: Node was not very hot. Surgeon did marginal excision around tumor site. Primary 






LAO 15MIN      LTLAT AX 20MIN 
 
 
LAO 25MIN      LAO ONSIDE 40MIN 
 










5x5 Patient: Br12 
Date of Study: 07/21/03 
Patient Initials: CH 
Patient History: Sister died of breast cancer @ 45yo. Six years ago distal left breast cancer. Right breast 
cancer found by mammography & core biopsy  
 Sex: F 
 Age: 56  
 Location of Tumor/Lesion: Right breast @ 9:00 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by Sandi 





Sample ID Indicators Post-ex count OR img activity Location 


















ANT 22MIN       RAO 26MIN 
 
 





       
 






TIFF name:    pre-excision  Interfile name:    BR12 
Image duration:    180 sec          Start time:    13:49:57 
TIFF name:  excised  node   Interfile name:    BR12 
Image duration:    180 sec          Start time:    14:02:19 
 
TIFF name:  postexcision   Interfile name:    BR12 
Image duration:    180 sec          Start time:    14:06:42 
 
TIFF name:  supraclavicular 1 Interfile name:    BR12 








TIFF name:  supraclavicular2  Interfile name:    BR12 
Image duration:    300 sec          Start time:    14:15:10 
 
TIFF name:  supraclavicular3  Interfile name:    BR12 





5x5 Patient: B13 
Date of Study: 07/22/03 
Patient Initials: TV 
Patient History: Lump found by routine mammography 06/03 
 Sex: F 
 Age:  
 Location of Tumor/Lesion: Left breast @1:00 ≈5mm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 









ANT 11MIN       LAO 16MIN 
 
 





LAO 28MIN       L LAT 35MIN 
 
 





       
 





TIFF name:    preincision   Interfile name:    BR13 
Image duration:    180 sec          Start time:    11:42:26 
 
TIFF name: pre-excision  Interfile name:    BR13 
Image duration:    180 sec          Start time:    11:52:59 
 
After the cut was made, but before mass was excised 
TIFF name: excised node  Interfile name:    BR13 
Image duration:    180 sec          Start time:    11:59:47 
 
 
TIFF name: post-excision  Interfile name:    BR13 





5x5 Patient: Br14 
Date of Study: 08/19/03 
Patient Initials: PM 
Patient History: Previous right breast tumor. Core biopsy left breast, nonpalpable 
 Sex: F 
 Age: 59 
 Location of Tumor/Lesion: Left breast @6:00 ≈1 cm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot/Blue 14632 Lt axilla 
1 Hot/Blue 701 
1107 
 Lt axilla 
2 Hot/Blue 9971 813 Lt axilla 
3 Hot/Blue 3614 77 Lt axilla 





















       
 






TIFF name:    preincision axillary    Interfile name: BR14 
Image duration: 190 sec          Start time:    12:25:15 
 
TIFF name:  preincision im    Interfile name: BR14 
Image duration: 181 sec          Start time:    12:29:47 
 
Image of intramammory nodes 
TIFF name:  excised nodes 1-3   Interfile name: BR14 
Image duration: 300 sec          Start time:    12:51:28 
 
 
TIFF name:  excised node 4    Interfile name: BR14 








     
 
TIFF name:  postexcision axillary   Interfile name: BR14 
Image duration: 180 sec          Start time:    13:05:37 
 
Nodes are still left in axillary 
TIFF name:  axillary contents dissected  Interfile name: BR14 
Image duration: 300 sec          Start time:    13:49:04 
 




5x5 Patient: Br15 
Date of Study: 08/20/03 
Patient Initials: HP 
Patient History: Nonpalpable 
 Sex: F 
 Age: 53 
 Location of Tumor/Lesion: Right breast behind nipple ≈4x6mm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot 1095 182 axillary 



































   
TIFF name:  excised node 1    Interfile name: BR15 
Image duration:  300 sec          Start time:    15:38:06 
 
TIFF name:  excised node 2    Interfile name:  BR15 






5x5 Patient: Br16 
Date of Study: 09/15/03 
Patient Initials: VN 
Patient History:  Palpable mass, sore to the touch 
 Sex: F 
 Age: 46 
 Location of Tumor/Lesion: Right breast @10:00 ≈2cm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot/Blue 22291 6496 axilla 
2 Hot/Blue 1449 595 axilla 
 
 
Comments/Discussion:  Sandi said there were a total of 6 nodes with in the 3masses and Bob said there 

























TIFF name: excised node 2    Interfile name:  BR16 
Image duration:  120 sec          Start time:    14:20:23 
 
 
TIFF name:  excised node 1   Interfile name: BR16 
Image duration:  148 sec          Start time:    14:14:41 
 
 
TIFF name: right axillary content   Interfile name:  BR16 






5x5 Patient: Br17 
Date of Study: 09/15/03 
Patient Initials: HN 
Patient History: Maternal aunt had breast cancer 
 Sex:  F 
 Age: 41 
 Location of Tumor/Lesion: Right breast @12:30 ≈1cm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 




Comments/Discussion: A mass was moved prior to sentinel node, it was blue but had no counts. Surgeon 














 RAO 39MIN       R LAT 47MIN 
 
 












       
 




TIFF name:  anterior preincision   Interfile name:  BR17 
Image duration:  300sec          Start time:    15:12:13 
 
 
TIFF name: mass 1 removed  Interfile name: BR17 
Image duration:    239 sec          Start time:    15:41:47 
 
There were no counts for the first mass removed in the OR 
TIFF name: mass 2 removed  Interfile name: BR17 
Image duration:    300 sec          Start time:   15:46:26 
 




5x5 Patient: Br18 
Date of Study: 09/16/03 
Patient Initials: SB 
Patient History: Core biopsy, Mother was a study patient 5 yrs ago 
 Sex:  F 
 Age: 43 
 Location of Tumor/Lesion: Right breast @6 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot/Blue 17661 4402 axilla 
3 Hot/Blue 945 102 axilla 
2 Hot/Blue 6387 1760 axilla 




Comments/Discussion:  Surgeon probably would not have moved as many nodes using only blue dye. With 

























   
 
TIFF name:   mass 1     Interfile name: BR18 
Image duration: 300 sec          Start time:    12:05:10 
 
 
TIFF name:  mass 2     Interfile name:  BR18 
Image duration:    300 sec          Start time:    12:11:45 
 
Mass 2 was sent to frozen section as SN #3 
TIFF name:  mass 3     Interfile name:  BR18 
Image duration:    300 sec          Start time:    12:19:04 
 
Mass 3 was sent to frozen section as SN #2 
TIFF name:  mass 4     Interfile name:  BR18 






5x5 Patient: Br19 
Date of Study: 11/18/03 
Patient Initials: TW 
Patient History: Mother had breast cancer at the age of 58. Palpable node, FNA 
 Sex: F 
 Age: 42 
 Location of Tumor/Lesion: Right breast @11:00 ≈1.3x1.2x1.1cm 
Surgeon: Styblo 
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot/Blue 18204 2949 axilla 
2 Hot 1917 177 axilla 
3 Hot 3318 279 axilla 
 
 
Comments/Discussion: Mass #3 was not sent up for frozen section. Surgeon noted the camera was helpful 






 ANT 7MIN       RAO 11MIN 
 
 



















TIFF name: preincision    Interfile name:  BR19 
Image duration: 120 sec          Start time:    12:33:48 
 
 
TIFF name: im preincision   Interfile name: BR19 
Image duration:    124 sec          Start time:    12:36:37 
 
Image of intramammery area 
TIFF name: mass 1    Interfile name: BR19 
Image duration: 180sec          Start time:    12:51:01 
 
 
TIFF name: mass 2    Interfile name: BR19 







   
TIFF name: mass 3    Interfile name: BR19 
Image duration: 120sec          Start time:    13:06:08 
 
 
TIFF name: post excision   Interfile name: BR19 






5x5 Patient: Br20 
Date of Study: 01/28/04 
Patient Initials: MW 
Patient History: NS 
 Sex: F 
 Age: 67 
 Location of Tumor/Lesion: left breast @3:00 ≈1cm 
Surgeon:  
Images/Data of study:  
 Preop Images: GE 500 by S. Grant 




Sample ID Indicators Post-ex count OR img activity Location 
1 Hot 3882 676 axilla 
 
 






LAO 15MIN      LTLAT AX 20MIN 
 
 
LAO 25MIN      LAO ONSIDE 40MIN 
 


















TIFF name:  preincision     Interfile name: BR20 
Image duration:  118sec          Start time:    13:06:16 
 
 
TIFF name: preincision 2    Interfile name:  BR20 
Image duration: 175 sec          Start time:    13:09:38 
 
 
TIFF name: excised node    Interfile name:  BR20 
Image duration: 300 sec          Start time:    13:25:35 
 
 
TIFF name: postexcision    Interfile name:  BR20 
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